Definitions

1. **Mole**
   - that number of molecules contained in 0.012 kg of C^{12}, or,
   - the molecular weight of a substance in grams = \textit{Avogadro's number} = 6.023 \times 10^{23}

2. **Solution**
   - a homogeneous mixture of 2 or more substances of dissimilar molecular structure
   - usually applied to \textit{solids} in \textit{liquids} but applies equally to \textit{gasses} in \textit{liquids}

3. **Crystallloid**
   - a non-colloid substance, which in solution,
   - i. passes readily through biological membranes
   - ii. displays \textit{colliagative properties} - see below
   - iii. is capable of being crystallised

4. **Colloid**
   - a solution where the particles of the \textit{disperse phase},
   - i. are larger than ordinary crystallloid molecules, but are not large enough to settle out under the influence of \textit{gravity}
   - ii. resist diffusion
   - iii. range in size from ~ 1 to 100 nm (or up to 1000 nm), the range being arbitrary
   - \textit{emulsion colloids}, where the particles of the disperse phase are made of highly complex organic molecules, which absorb much of the dispersion medium, usually water, swell, and become uniformly distributed throughout and the dispersion medium
   - \textit{suspension colloids}, where the particles of the disperse phase are made of any \textit{insoluble} substance, such as a metal, and the dispersion medium may be gaseous, liquid or solid

5. **Molality**
   - is the number of moles of solute per \textit{kilogram} of \textit{solvent}

6. **Molarity**
   - is the number of moles of solute per \textit{litre} of \textit{solution}

7. **Diffusion**
   - the constant random thermal motion of molecules, which leads to the net transfer of molecules, from a region of higher to a region of lower \textit{thermodynamic activity}

8. **Osmosis**
   - the movement of a \textit{solvent} across a semipermeable membrane, down a thermodynamic activity gradient for that solvent

9. **Osmotic Pressure**
   - the \textit{hydrostatic} pressure which would be required to prevent the movement of a solvent across a semipermeable membrane, down a thermodynamic activity gradient for that solvent
10. **Tonicity**  
   - the effective osmotic pressure of a solution, relative to plasma  
   - usually referenced to red blood cells

11. **Colligative Properties**  
   - are those properties of a solution which depend only upon the number of freely moving particles, and not on the nature of the particles themselves,  
   i. osmotic pressure  
   ii. depression of freezing point  
      - commonly used to calculate osmolality  
      - 1 mosmol/kg → 1.86 °C depression of the freezing point of pure water  
   iii. elevation of boiling point  
   iv. depression of saturated vapour pressure

12. **Osmole**  
   - the weight in grams of a substance producing an osmotic pressure of 22.4 atm. when dissolved in 1.0 litre of solution, or,  
   - \( \text{osmole} = \frac{\text{gram molecular weight}}{\text{no. of freely moving particles per molecule}} \)

13. **Osmotic Coefficient**  
   - the degree of dissociation of a particular compound  
   - eg., NaCl → 1.86 particles when dissolved in pure water  
   \[ \text{OC}_{\text{NaCl/H}_2\text{O}} = 0.93 \]

14. **Osmolality**  
   - the number of osmoles of solute per kilogram of solvent

15. **Osmolarity**  
   - the number of osmoles of solute per litre of solution
BODY FLUIDS

<table>
<thead>
<tr>
<th></th>
<th>Normal Values</th>
<th>Premature</th>
<th>Term</th>
<th>25 yrs</th>
<th>45 yrs</th>
<th>65 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TBW</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male:</td>
<td>80%</td>
<td>75%</td>
<td>60%</td>
<td>55%</td>
<td>50%</td>
<td>45%</td>
</tr>
<tr>
<td>Female:</td>
<td>50%</td>
<td>55%</td>
<td>47%</td>
<td>45%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ECF</strong></td>
<td>45%</td>
<td>40%</td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ICF</strong></td>
<td>35%</td>
<td>35%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood Volume</strong></td>
<td>90-100 ml/kg</td>
<td>85 ml/kg</td>
<td></td>
<td></td>
<td>~ 70 ml/kg</td>
<td></td>
</tr>
</tbody>
</table>

- neonates reach adult values by 2 yrs and are about half-way by 3 months
- average values ~ 70 ml/100g of lean body mass
- percentage of water varies with tissue type,
  a. lean tissues ~ 60-80%
  b. bone ~ 20-25%
  c. fat ~ 10-15%

Distribution of TBW

```

```

<table>
<thead>
<tr>
<th></th>
<th>Dense CT</th>
<th>Interstitial Fluid</th>
<th>Plasma</th>
<th>Transcellular</th>
</tr>
</thead>
<tbody>
<tr>
<td>~ 7.5%</td>
<td>~ 55%</td>
<td>~ 20%</td>
<td>~ 7.5%</td>
<td>~ 2.5%</td>
</tr>
</tbody>
</table>

RBC's ~ 4.4%
• distribution between various body compartments, percentage of TBW
  
a. Intracellular Fluid ~ 55%
   i. RBC's ~ 4.4%
   ii. Others ~ 50.6%

b. Extracellular Fluid ~ 45%
   i. Interstitial ~ 20%
   ii. Plasma ~ 7.5%
   iii. Bone & Cartilage ~ 7.5%
   iv. Dense CT. ~ 7.5%
   v. Transcellular ~ 2.5%

- **Simplified Distribution for Fluid Therapy**
  
  • bone, cartilage and dense connective tissue exchange slowly with the intravascular compartment
  • thus, for the purpose of fluid therapy the follow distribution may be assumed

<table>
<thead>
<tr>
<th>ICF ~ 2/3</th>
<th>ECF ~ 1/3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Interstitial ~ 3/4</td>
<td></td>
</tr>
<tr>
<td>Intravascular ~ 1/4</td>
<td></td>
</tr>
</tbody>
</table>
Measurement of Compartments

- most techniques involve \textit{indicator dilution}, whereby a given \textit{volume of distribution} is calculated
- this method is based upon the \textit{conservation of mass} principal, where the $V_{dl}$ for an indicator is given by,

\[ V_{dl} = \frac{\text{Mass Injected} - \text{Mass Lost}}{[I]_{\text{Plasma}}} \]

\textit{NB:} the derived volumes are estimations only, and when stated should actually be stated as such, eg. the "12 hour tritium oxide volume", not TBW

- \textbf{Total Body Water}
  - accurate estimation can only be derived from \textit{desiccation} of cadaver specimens
  - one of three indicators is usually used and results acceptably concur with to desiccation experiments,
    - a. \textit{deuterium oxide} - measured by mass spectroscopy
      - cumbersome and more difficult
    - b. \textit{tritium oxide} - weak $\beta$ emitter and easily measured
      - radiation half-life \(\sim 12.4\) years
      - biological half-life \(\sim 10\) days
      - therefore small total radiation dose
    - c. \textit{antipyrene} - \(\sim 4\) hrs equilibrium, 6-8 hrs in the obese
      - measured by spectroscopy

- \textbf{Extracellular Fluid}
  - quite difficult to measure as \textit{no} indicator is truly confined to the ECF
  - use either crystalloids or ionic substances,
    - a. radioactively labelled inulin
    - b. radioactively labelled mannitol
    - c. $^{82}\text{Br}^-$
    - d. $^{36}\text{Cl}^-$
    - e. $^{38}\text{Cl}^-$
  - $\text{Br}^-$ and $\text{Cl}^-$ are distributed similarly, however not all $\text{Cl}^-$ is extracellular and some cells contain quite high concentrations, eg. RBCs
  - some workers in fact argue that RBC's should be included with the ECF due to this property
  - the biological half-life of $^{82}\text{Br}^-$ is more favourable than either of the isotopes of $\text{Cl}^-$
■ **Plasma Volume**

- use *plasma protein* bound markers, though, ~ 7-10% leaves the vascular compartment per hour
- this value is increased in a number of disease states
- therefore, equilibration time is kept to a minimum → ~ 15 mins
- alternatively, serial measures are taken and the plasma concentration extrapolated to time = 0
- markers include,
  a. radiolabelled serum albumin
  b. Evans blue labelled serum albumin
  c. radiolabelled globulins

■ **Red Blood Cell Volume**

- RBCs labelled with either $^{51}$Cr, $^{59}$Fe++, or $^{32}$P
- alternatively may be labelled *antigenically*

---

**NB:** the remaining volumes cannot be calculated directly and are therefore *derived* from the above volumes

<table>
<thead>
<tr>
<th>Equation</th>
<th>Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Intracellular Volume</td>
<td>$\text{TBW} - \text{ECF}$</td>
</tr>
<tr>
<td>2. Interstitial Volume</td>
<td>$\text{ECF} - \text{Plasma Volume}$</td>
</tr>
<tr>
<td>3. Blood Volume</td>
<td>$\text{Plasma Volume} + \text{RBC Volume}$</td>
</tr>
<tr>
<td></td>
<td>$= 1/(1 - \text{Hct.})$</td>
</tr>
</tbody>
</table>
REGULATION OF BODY WATER

- factors include,
  1. Diffusion
  2. Gibbs-Donnan Equilibrium
  3. Osmosis
  4. Ion pumps
  5. Starling’s forces

- **Diffusion**
  - water crosses all cell membranes freely, except the conducting tubules of the nephron and bladder
  - membranes are variably permeable to solutes, depending upon their charge, size and the presence of specific membrane channels
  - the effective size of an ion is determined by its hydrated radius, rather than its actual size
  - the degree of hydration is determined by the charge density of the given ion, eg,
    a. $^{23}\text{Na}^+ \rightarrow \text{HR} \sim 0.28 \text{ nm}$
    b. $^{39}\text{K}^+ \rightarrow \text{HR} \sim 0.35 \text{ nm}$

- **Gibbs-Donnan Equilibrium**

  **Def’n:** "in the presence of a non-diffusible ion, the diffusible ion species distribute themselves such that at equilibrium their concentration ratios are equal", viz.

<table>
<thead>
<tr>
<th>Side A</th>
<th>Side B</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{Na}^+$</td>
<td>$\text{Na}^+$</td>
</tr>
<tr>
<td>$\text{Cl}^-$</td>
<td>$\text{Cl}^-$</td>
</tr>
<tr>
<td>$\text{Pr}^-$</td>
<td></td>
</tr>
</tbody>
</table>

  **NB:** Donnan effect dictates that, $[\text{Na}^+]_A[\text{Cl}^-]_A = [\text{Na}^+]_B[\text{Cl}^-]_B$

  thus, $\frac{[\text{Na}^+]_A}{[\text{Na}^+]_B} = \frac{[\text{Cl}^-]_B}{[\text{Cl}^-]_A}$

  but to maintain electroneutrality, $[\text{Na}^+]_B = [\text{Cl}^-]_B$

  therefore, $[\text{Na}^+]_A > [\text{Cl}^-]_A$
the net effects of this distribution are that, on the side of the **non-diffusible species**, there is,

a. an increase in the number of osmotically active particles  
b. an increase in the [cations]  
c. a decrease in the [anions]  
d. a **charge difference** across the membrane

*NB:* → albumin acts as if its MW ~ 37,000, c.f. its actual MW ~ 69,000

- the predicted difference in concentrations between plasma and the interstitial fluid are ~ 5%  
- in reality the measured [Na⁺] in the plasma and the ISF are approximately **equal**  
- this occurs as the G-D equilibrium refers to thermodynamic activity, which approximates water concentrations for dilute solutions, and ~ 7% of the plasma volume is protein  
- thus, the actual plasma water [Na⁺] is **higher** than that measured

### Osmosis

- at equilibrium, all fluid compartments which allow free water movement across their membranes will be virtually **isotonic**  
- Na⁺ and its anions are the major determinants of ECF osmolality  
- K⁺ and its anions are the major determinants of ICF osmolality  
- plasma **oncotic pressure** is the effective osmolality which exists across most capillary membranes due to the relative impermeability to proteins  
  → average value ~ 25 mmHg

- maintained by, but effectively opposes, the capillary hydrostatic pressure  
- contributed to principally by,  
  a. albumin ~ 65%  
  b. globulins ~ 15%

### Ion Pumps

- these maintain the transcellular ion balances  
- the presence of non-diffusible species within cells would lead to a net inward flux of water, with subsequent swelling and rupture  
- a number of ion pumps, mainly the Na⁺-K⁺-ATPase, allow cells to maintain isotonicity  
- the net effect of this is that cells exist at steady state, away from the lowest energy equilibrium state for the system, further a potential difference exists across the cell membrane  
- the loss of function of these pumps, eg. hypoxia, leads to cellular oedema


- **Starling's Forces**

  - this equation predicts the net flux of water across a membrane,

    \[ J_v = K_f \cdot [(P_c - P_i) - \sigma(\pi_c - \pi_i)] \]

  where,
  - \( J_v \) = net water flux
  - \( K_f \) = the filtration coefficient
  - \( P_{ci} \) = hydrostatic pressures
  - \( \pi_{ci} \) = oncotic pressures
  - \( \sigma \) = Staverman reflection coefficient

  - the Staverman reflection coefficient is a measure of capillary permeability to protein,
    \[ \sigma = 1 \rightarrow \text{completely impermeable} \]

  - most studies assume a value of 1, ignore \( K_f \), and simply refer to the net balance of forces which determine flow across the capillary
  - this is invariably an over-simplification, quoted figures for lung varying from,
    
    i. lung capillary  \( \rightarrow \) 2 to 12 mmHg
    ii. lung interstitial  \( \rightarrow \) -7 to 1 mmHg
    iii. plasma oncotic  \( \rightarrow \) 20 to 35 mmHg
    iv. interstitial  \( \rightarrow \) 5 to 18 mmHg

    **NB:** this gives a total range of net driving pressure from **-29 to 17** mmHg

  - the lung interstitial pressures are probably slightly negative
  - interstitial protein concentrations vary considerably between tissues
  - those in the lung are probably ~ 70-80% of plasma (Nunn ~ 50%)
  - 99% of the interstitial fluid does not exist as free fluid but as a gel, mainly composed of hyaluronic acid cross-linked with collagen
  - thus, the ISF space can only accommodate small increases in volume before ISF pressure rises

  **NB:** Starling's equation predicts the net movement of fluid across the capillary, it does not predict what happens to ISF volume

  - this will only increase if lymphatic drainage is unable to accommodate the increase in flow
  - the ability of the lymphatic system to increase flow also varies with tissue, the lung having the greatest reserve  \( \rightarrow \) 20 fold increase
  - this increase occurs within the ISF pressure range of ~ 0-4 mmHg
  - lymphatics possess the ability to pump fluid from the ISF, partly explaining the negative pressure of some tissue beds

  - the high pulmonary ISF protein concentration serves as a safety mechanism
  - increases in flow washing out protein, reducing ISF oncotic pressure and the net driving pressure
  - this has been supported by experimental work which shows that the capillary/ISF protein ratio returns to "normal" within ~ 3 hours of artificial lowering of COP
the BBB is unique in that there is normally a total impermeability to protein, as well as a number of ions, and there is no lymphatic system

- the result of this is that variations in COP have little effect in cerebral oedema, however, changes in plasma osmolality may have a large effect

- the BBB ion pumps and the generation of idiogenic osmoles account for the chronic adaptation of the brain to changes in plasma osmolality

---

**Common Intravenous Solutions**

<table>
<thead>
<tr>
<th>Solution</th>
<th>Na⁺</th>
<th>Cl⁻</th>
<th>K⁺</th>
<th>Ca++</th>
<th>Glu</th>
<th>Osm.</th>
<th>pH</th>
<th>Lact.</th>
<th>kJ/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>D₅W</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>278</td>
<td>253</td>
<td>5</td>
<td>0</td>
<td>840</td>
</tr>
<tr>
<td>NaCl 0.9%</td>
<td>150</td>
<td>150</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>300</td>
<td>5.7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NaCl 3.0%</td>
<td>513</td>
<td>513</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>855</td>
<td>5.7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>D₅W / NaCl 0.18%</td>
<td>30</td>
<td>30</td>
<td>0</td>
<td>0</td>
<td>222</td>
<td>282</td>
<td>3.5-5.5</td>
<td>0</td>
<td>672</td>
</tr>
<tr>
<td>Hartmans</td>
<td>129</td>
<td>109</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>274</td>
<td>6.7</td>
<td>28</td>
<td>37.8</td>
</tr>
<tr>
<td>Plasmalyte</td>
<td>140</td>
<td>98</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>294</td>
<td>5.5</td>
<td>(27)</td>
<td>84</td>
</tr>
<tr>
<td>Haemaccel</td>
<td>145</td>
<td>145</td>
<td>5.1</td>
<td>6.25</td>
<td>0</td>
<td>293</td>
<td>7.3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NSA-5%</td>
<td>140</td>
<td>125</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>?</td>
</tr>
<tr>
<td>NSA-20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>Mannitol 20%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,098</td>
<td>6.2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dextran 70%</td>
<td>154</td>
<td>154</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>300</td>
<td>4-7</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

1 values in mmol/l, irrespective of common presentation volume

- Plasmalyte: Na⁺ ~ 140 Gluconate ~ 23
- Cl⁻ ~ 98 Acetate ~ 27
- K⁺ ~ 5 Osmo ~ 294
- Mg²⁺ ~ 1.5 pH ~ 5.5
- kJ ~ 84
Water Metabolism

**NB:** Daily Balance: \( \rightarrow \) turnover \( \sim 2500 \text{ ml} \)

a. **Intake**
   i. drink \( \sim 1500 \text{ ml} \)
   ii. food \( \sim 700 \text{ ml} \)
   iii. metabolism \( \sim 300 \text{ ml} \)

b. **Losses**
   i. urine \( \sim 1500 \text{ ml} \)
   ii. skin \( \sim 500 \text{ ml} \)
      - insensible losses \( \sim 400 \text{ ml} \)
      - sweat \( \sim 100 \text{ ml} \)
   iii. lungs \( \sim 400 \text{ ml} \)
   iv. faeces \( \sim 100 \text{ ml} \)

- minimum daily intake \( \sim 500 \text{ ml} \) with a "normal" diet
- minimum losses \( \sim 1500 \text{ ml/d} \)
- losses are increased with,
  a. increased ambient T
  b. hyperthermia \( \sim 13\% \) per °C
  c. decreased relative humidity
  d. increased minute ventilation
  e. increased MRO\(_2\)

**Plasma Osmolality**

- plasma osmolality is \( \equiv \) to total body osmolality, as virtually all of TBW is in equilibrium,

\[
T_{\text{osm}} = \frac{\text{ECF solute} + \text{ICF solute}}{\text{TBW}}
\]

- exchangeable Na\(^+\) and K\(^+\) and their anions account for most of these solutes
- water balance is the prime determinant of osmolality and the plasma [Na\(^+\)]

**NB:** thus, Na\(^+\) balance determines ECFV
Controls of Water Balance

**Intake**

- altered by the thirst mechanism
- the hypothalamic centres are closely related to those controlling ADH release
  
  a. Osmotic - $\delta$ osmolality $\sim$ 1%
  
  b. Non-osmotic
  
  i. effective ECFV - arterial baroreceptors
     - venous baroreceptors
     - angiotensin II
     - ADH
  
  ii. electrolytes - thirst $\sim$ $[Ca^{++}]$  
     - thirst $\sim$ $1/[K^+]$
  
  iii. hyperthermia
  
  iv. hypoxia
  
  v. drugs - ETOH decreases
     - chlorpropamide increases

**Losses**

a. ADH - major controlling factor, see below

b. glucocorticoids
   
   - their exact role in water maintenance is uncertain
   - in deficiency states, replacement of mineralocorticoid alone is insufficient to restore normal water balance
ADH Secretion Regulation of Osmolality & ECF Volume

- although protection of the ECF is linked to the Na\(^+\) mass, the ability of water to follow Na\(^+\) reabsorption is dependent on secretion of ADH
- therefore, decreases in plasma volume reflexly increase both aldosterone and ADH
- ADH, or arginine vasopressin, is an nonapeptide synthesised by discrete neurones in the supraoptic > paraventricular nuclei of the hypothalamus
- axons terminate in the posterior pituitary from where ADH reaches the blood-stream
- synthesised as a large and inactive prohormone + neurophysin + glycopeptide
- these are stored in granules and split to ADH-neurophysin during passage from the perikaryon to the terminal bulbs, neurophysin also binds oxytocin
- newly synthesised hormone appears in the posterior lobe within ~ 30 mins of a stimulus such as haemorrhage
- mechanism of vesicle release = depolarisation → Ca\(^{++}\) influx → exocytosis
- some neurones also terminate in the external zone of the median eminence, from where ADH enters the adenohypophyseal portal circulation and acts as an ACTH releasing factor (CRF)
- ADH undergoes rapid enzymatic cleavage in vivo, mainly in the liver and kidney
  → vasopressinase
- deamination at the 1AA reduces its susceptibility to peptidases and substitution of \(d\)-Arg for \(l\)-Arg at the 8AA reduces pressor activity,
  → desmopressin DDAVP

\(NB:\) there are two principal physiological mechanisms for release,

1. hyperosmolality
2. hypovolaemia

### Hyperosmolality

- Verney (1947) showed that a ≤ 2\% increase in osmolality in the hypothalamus produced a sharp antidiuresis on dogs
- current candidates for the osmoreceptors of the hypothalamus are,
  a. the organum vasculosum of the lamina terminalis (OVLT)
  b. the subfornical organ (SFO)

- both of which are outside the blood brain barrier
- the threshold for secretion is ~ 280 mosmol/l
- individuals vary but below this level ADH is virtually undetectable
- above this level [ADH] rises sharply and linearly with plasma osmolality
- there is also evidence for a direct functional interaction between neural centers for thirst and ADH secretion
- drinking decreases ADH release before any change of plasma osmolality
**Volume Depletion**
- haemorrhage, Na⁺ depletion, or other acute causes of decreased ECF volume, irrespective of plasma osmolality, increase release of ADH
- secretion appears to come from a readily releasable "pool" of hormone, which approximates 10-20% of ADH in the pituitary, subsequent release is at a slower rate
- other chronic conditions in which effective circulating volume is reduced are also associated with elevated levels of ADH,
  i. CCF
  ii. cirrhosis with ascites
  iii. hypothyroidism
  iv. excessive diuresis
  v. adrenal insufficiency
- receptors include the baroreceptors of left atrium, pulmonary veins, also the carotid sinus and aortic arch
- the afferent pathways are in the vagus and glossopharyngeal nn.
- secretion of ADH is under tonic inhibitory control of the baroreceptors
- secretion in response to hypoxia, nausea and pain may also be mediated by receptors in the carotid sinus and aortic arch
- iso-osmotic contraction of the ECF produces little secretion < 10% change, after which [ADH] increases rapidly and exceeds the response due to osmolar stimulation
- levels produced under these circumstances are high enough for ADH to have a direct pressor effect on vascular smooth muscle

**Other Mediators of ADH Release**
- mechanisms for which there is good evidence for stimulation of release include,
  a. angiotensin II - synthesised by brain as well as peripherally
  b. dopamine
  c. endogenous opioids, pain/"stress"
  d. hyperthermia
  e. hypoxia
  f. nausea
  g. drugs - either stimulate or inhibit secretion

<table>
<thead>
<tr>
<th>Stimulat*:</th>
<th>Inhibit*:</th>
</tr>
</thead>
<tbody>
<tr>
<td>tricyclics</td>
<td>ethanol</td>
</tr>
<tr>
<td>vincristine, vinblastine</td>
<td>phenytoin</td>
</tr>
<tr>
<td>loop diuretics</td>
<td>glucocorticoids</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>mineralocorticoids</td>
</tr>
<tr>
<td>colchicine</td>
<td></td>
</tr>
<tr>
<td>chlorpropamide</td>
<td></td>
</tr>
</tbody>
</table>
- release is inhibited by GABA → inhibitory interneurone is GABA'ergic
- prostaglandins may play a role in both osmotic and volumetric release of ADH
Renal Effects of ADH

- after release into the circulation → $t_{ps} \sim 17$ to 35 mins
- removed by enzymatic cleavage and receptor binding in smooth muscle
- smooth m. and hepatic receptors = V$_1$ receptors and act via phosphoinositol phosphate and Ca$^{++}$
- V$_2$ receptors in the kidney act via adenylate cyclase & cAMP
- water reabsorption in the cortical CT and beyond is governed by permeability of the luminal membrane under the influence of ADH:
  1. high [ADH] - mass diffusion of water, urine iso-osmotic to medulla
  2. low [ADH] - limited diffusion of water, large volume of dilute urine
     - virtually no H$_2$O reabsorbed after loop of Henle

- achievable osmolality,
  a. minimal ~ 50 mosmol/kg
     - as much as 15% of filtered water may appear in the urine (15% of 180 l/d = 27l)
  b. maximal ~ 1200-1400 mosmol/kg
     - corresponding to the medullary interstitium

- proposed sequence of events,
  a. V$_2$ receptors on basolateral membrane activate adenylate cyclase
  b. increase in [cAMP],
  c. activated cAMP-dependent protein kinase ± phosphoprotein phosphatase
  d. microtubules and microfilaments important in ADH response
  e. aggregation of proteins at luminal membrane
  f. ? insertion or phosphorylation of membrane protein channels
  g. increased permeability of luminal membrane

- ADH in physiological concentration has virtually no effect on Na$^+$ transport
- ADH may promote Na$^+$ and water retention by a reduction in GFR secondary to contraction of afferent arterioles and mesangial cells
- ADH exerts local (-)ve feedback due to induction of medullary synthesis of prostaglandins, the later opposing ADH induced generation of cAMP
- altered PG synthesis may therefore account for the altered tubular responsiveness seen in various disease states
- eg. hypovolaemic shock associated high output renal failure
Non-Renal ADH Effects

- volume depletion may produce a high [ADH] with direct pressor effects on vascular smooth m.
- its effects on the heart are indirect → reduced coronary flow and reflex alterations in SNS/PNS
- also contracts smooth m. of the GIT and uterus
- increases Factor VIII concentrations in haemophilia and von Willebrand's disease, therefore may be used as a prophylactic during surgery
- increases platelet activity in renal failure, post-transfusion etc
- may play a role in regulation of ICP by altering the permeability of the arachnoid villi to water
- possible role as a neurotransmitter, eg. CRF in the pituitary

DDAVP Desmopressin

- chemically modified ADH = 1-deamino-8-d-arginine vasopressin,  
  a. deamination results in resistance to plasma and hepatic proteases
     - resultant long plasma half life $t_{1/2} \approx 76$ minutes  
  b. d-arginine greatly reduces vasoactive properties

- the duration of drug effect ~ 8 to 20 hrs
- intranasal bioavailability ~ 10%
- the dose for central DI is 10-40 µg/d nasally, or 1/10th this amount IM
- for children the dose is ~ ¼ to ½ this amount

- for the procoagulant effects, an infusion of 0.4 µg/kg in 100 ml of NaCl, over 20 mins is usually sufficient to raise VIII:C, VIIIR:Ag and decrease the SBT
- further doses may be given 12 hrly as required
- indicated for haemophilia A and von Willebrand's d. but not for type II von Willebrand's disease, as platelet aggregation may be induced
## Summary of ADH Effects

<table>
<thead>
<tr>
<th>Receptor Subtype</th>
<th>Second Messenger</th>
<th>Physiological Effects</th>
</tr>
</thead>
</table>
| $V_1$            | $IP_3 / Ca^{++}$ | - vasoconstriction especially coronary, mesenteric & skin  
|                  |                  | - glycogenolysis      |
| $V_2$            | cAMP protein kinase ± phosphoprotein phosphatase | - increased DT/CD $H_2O$ permeability  
|                  |                  | - increased renal PGE$_2$ (opposes above)  
|                  |                  | - increased PRA  
|                  |                  | - tachycardia  
|                  |                  | - facial flushing  
|                  |                  | - lowered BP  
|                  |                  | - increased PGI$_2$  
|                  |                  | - increased fibrinolytic activity (tPA)  
|                  |                  | - increased Factor VIII related antigen  
|                  |                  | - increased Factor VIII coagulant activity  
|                  |                  | - increased von Willebrand factor multimers |
| $V_3$            | ??               | - baroreceptor modulation  
|                  |                  | - ? behavioural effects |

---

**Fluids & Electrolytes**

17
**Osmolar Clearance**

*Def'n:* is the *volume* of urine necessary to excrete the osmotic load in a urine which is *iso-osmolar* with plasma, viz.

\[ C_{\text{osm}} = \frac{U_{\text{osm}} \times V_U}{P_{\text{osm}}} \]

**Free Water Clearance**

*Def'n:* \( C_{\text{FW}} \) is equal to the urine volume minus the osmolar clearance, viz.

\[ C_{\text{FW}} = V_U - \frac{U_{\text{osm}} \times V_U}{P_{\text{osm}}} \]

\[ \approx -1.9 \text{ to } 21 \text{ l/d} \]

- this may be inaccurate with a highly concentrated urine, as the majority of solute may be *urea*
- urea is freely permeable and does not affect *tonicity*, nor the distribution of body water
- therefore, we are really interested in the electrolyte free clearance of water

**Electrolyte Free Water Clearance**

\[ C_{\text{EFW}} = V_U - \frac{U_{Na+K} \times V_U}{P_{Na+K}} \]

- urea is ignored in this equation, although it may increase urine volume as an obligatory solute
- this better predicts water balance and its effects on plasma [Na+]
SODIUM

i. alkaline elemental metal
ii. atomic number = 11
iii. molecular weight ~ 23
iv. monovalent cation = the principal extracellular cation

- total body content ~ 58 mmol/kg,
  a. exchangeable ~ 70%
  b. ECF ~ 50%
  c. ICF ~ 5-10%
  d. bone ~ 40-45%

- concentration ranges vary between tissues,
  a. plasma ~ 132-146 mmol/l
  b. ICF ~ 3-20 mmol/l
     • muscle ~ 3-4 mmol/l
     • rbc ~ 20 mmol/l
  
- daily requirements ~ 2 mmol/kg/d (150 mmol/d)
- minimum requirement ~ 5-10 mmol/d

Control of Sodium Balance

1. intake - essentially unregulated in humans
2. losses
   i. renal
      • GFR → glomerulo-tubular balance
      • aldosterone - angiotensin II
         - hyperkalaemia
         - ACTH
         ? hyponatraemia
      • ANF ∝ atrial stretch, CVP
   ii. GIT
      • normal losses ~ 5-10 mmol/d
      • can markedly increase in disease states, eg. the secretory diarrhoeas (cholera)
   iii. sweat - insensible fluid losses are pure H₂O ~ 400 ml/d
      - [Na⁺]ₐw is directly proportional to rate

NB: control of Na⁺ excretion is via two variables, GFR and sodium reabsorption, the later being quantitatively more important
Regulation of ECF Volume

**NB:** as Na$^+$ is actively pumped from cells and the intracellular [Na$^+$] is low, so the total extracellular fluid volume depends primarily upon the mass of extracellular Na$^+$, which in turn correlates directly with the total body Na$^+$

- there are Na$^+$-sensitive receptors in the body, (adrenal cortex, macula densa and the brain), but these are less important in Na$^+$ regulation as these respond to the [Na$^+$], not the total mass of Na$^+$ in the body
- total ECF volume is not monitored directly, its components, the *intravascular* and *interstitial* volumes are
- as Na$^+$ is not secreted by the tubules,

\[
\text{Na}^+ \text{ excretion } = (\text{GFR} \times [\text{Na}^+]_{pl}) - \text{Na}^+ \text{ reabsorbed}
\]

- although [Na$^+$]$_{pl}$ may alter significantly in disease states, in most physiological states it is relatively constant
- therefore, control of excretion is via two variables, GFR and *Sodium Reabsorption*, the later being quantitatively more important

Control of GFR  
(see renal physiology notes)

<table>
<thead>
<tr>
<th>Direct Determinants of GFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\text{GFR} = K_F \times (P_{GC} - P_{BC} - \pi_{GC})$</td>
</tr>
</tbody>
</table>

**$K_F$**
- contraction/relaxation of mesangial cells alters SA & $K_F$
  \[ \rightarrow \text{ proportional changes in GFR} \]

**$P_{GC}$**
- $\uparrow$ renal a. pressure
- $\downarrow$ afferent aa. resistance
- $\uparrow$ efferent aa. resistance
  \[ \uparrow \text{ GFR} \]

**$P_{BC}$**
- $\uparrow$ intratubular pressure
  \[ \downarrow \text{ GFR} \]

**$\pi_{GC}$**
- $\uparrow$ plasma oncotic pressure
  \[ \rightarrow \text{ sets initial } \pi \]
- $\downarrow$ total renal plasma flow
  \[ \rightarrow \text{ determines rate of rise of } \pi \]
  \[ \downarrow \text{ GFR} \]

\[^1\] effects of changes in $K_F$ may be greatly reduced where NFP reaches *filtration pressure equilibrium*, as GFR results from only a part of available SA anyway
Control of Tubular Sodium Reabsorption

- **Glomerulotubular Balance (GTB)**
  - this is one reason for the lesser importance of alterations of the filtered load of Na⁺
  - the absolute reabsorption of solute and water in the PTs, and probably the loops of Henle and DTs, varies directly with the GFR
  - that is, the percentage of filtrate reabsorbed proximally remains at ~ 65%
  - this requires no external neural or hormonal input, occurring in the isolated kidney
    - **NB:** the effect is to blunt large changes in Na⁺ excretion secondary to changes in GFR, though, GFR is still does affect Na⁺ excretion, as,
      1. the absolute quantity of Na⁺ leaving the PT does alter
      2. GTB is not perfect, reabsorption does change with GFR

- therefore,
  1. *autoregulation* prevents large changes of GFR with δBP
  2. *GTB* prevents large changes in Na⁺ excretion with δGFR
    - **NB:** 2 lines of defence against profound haemodynamic alterations of Na⁺ excretion

- **Aldosterone**
  - this is the single most important controller of Na⁺ balance
  - produced in the adrenal cortex, in the zona glomerulosa and stimulates Na⁺ reabsorption in the late DTs and the CTs (probably not in the medulla)
  - proximal to this site of action, ≥ 90% of the filtered Na⁺ has already been reabsorbed
  - therefore, the total quantity of Na⁺ reabsorption dependent on aldosterone is ~ 2% of the filtered load, viz.
    \[
    2\% \text{ of } (\text{GFR} \times [\text{Na}^+]_{pl}) = (0.02)(180 \text{ l/d})(145 \text{ mmol/l}) = 522 \text{ mmol/d} \approx 30 \text{ g NaCl/d}
    \]
  - aldosterone also stimulates Na⁺ transport in other epithelia,
    1. sweat glands
    2. salivary glands
    3. the intestine
  - similarly, the effect is to reduce the luminal [Na⁺]
  - like other steroids, aldosterone combines with a *cytosolic receptor*, migrates to nucleus, increases synthesis of specific *mRNA* with subsequent *protein synthesis*
  - the mode of action of this protein may involve,
    1. ? activation of luminal Na⁺-channels
    2. increased [Na⁺]ᵢₑᶠ
    3. a 2° increased activity of basolateral Na⁺/K⁺-ATPase
there is also a direct effect on activity of Na\(^+\)/K\(^+\)-pump which occurs over a longer time span
this effect takes ~ 45 mins, due to the requirement for protein synthesis
therefore, decreases in Na\(^+\) excretion occurring in minutes, eg. orthostatic, are not due to aldosterone
four direct inputs to the adrenal regulate aldosterone secretion,
1. angiotensin II → most important factor
2. ↑ plasma [K\(^+\)] → stimulation
3. ACTH → permissive
4. ↑ plasma [Na\(^+\)] → inhibition
the effects of [Na\(^+\)] are minor in humans, [K\(^+\)] being far more important
ACTH stimulates release only when present in high concentrations
more importantly it is permissive for other factors within the physiological range
NB: however, ACTH secretion is not keyed to Na\(^+\) balance
other possible factors in release include β-endorphin, β-lipotropin and dopamine
the former two are secreted with ACTH as products of POMC
angiotensin II is by far the most important controller of aldosterone secretion in Na\(^+\) balance
accordingly, aldosterone secretion is largely determined by the release of renin, which is determined by,
1. intrarenal baroreceptors ↑
2. the macula densa ↑
3. the renal sympathetic NS ↑
4. angiotensin II ↓
Other Factors Influencing Tubular Na⁺ Handling

- **Atrial Natriuretic Factor**
  - 26 AA peptide hormone (sources range 24-28)
  - synthesised from a 126 AA prohormone in atrial secretory granules
  - released in response to atrial stretch / wall tension
  - plasma half life, $t_{1/2} \sim 3$ mins
  - clearance $\sim 34$ ml/kg/min
  - maximal natriuresis is less than that seen with frusemide, however ANF is $\sim 100$ times as potent
  - receptors are concentrated in cortical glomeruli
  - the postulated second messenger is cGMP
  - ? there is no direct effect upon Na⁺ transport, or the Na⁺/K⁺-ATPase
  - neither amiloride nor prostaglandin inhibitors have an effect upon its actions
  - ANF effects include,
    - a. systemic vasodilatation - transient hypotension IVI
    - predominantly venodilatation
    - decreases cardiac preload
    - b. increases GFR/RBF ratio - efferent vasoconstriction
    - afferent vasodilatation
    - increases filtration fraction
    - increases salt delivery to DT
    - c. increases $K_F$
    - d. increases MBF/CBF
    - e. decreases plasma renin - direct & indirect
    - f. decreases plasma aldosterone - direct & indirect
    - g. increases urinary excretion of - Na⁺, Cl⁻, K⁺
      - Ca²⁺, HPO₄⁻, Mg²⁺
    - h. increases urine volume

- **Effects of Angiotensin II**
  - a. vascular smooth muscle - increased tone
  - b. CNS/PNS - facilitation of sympathetic activity
  - c. adrenal cortex - increased secretion of aldosterone
  - d. kidneys
    - i. aa. constriction decreasing GFR but increasing GRF/RPF ratio
    - ii. direct tubular effect increasing Na⁺ reabsorption
  - e. brain - stimulates secretion of ADH
  - stimulates thirst

**NB:** all of which favour retention of salt and water and elevation of BP
Additional Factors

1. intrarenal physical factors
   - the interstitial hydraulic pressure, while favouring the final bulk flow of reabsorbed solute & water into the capillaries, also produces back-diffusion and when elevated is associated with a reduced overall level of fluid reabsorption
   - the two main factors governing this pressure are the peritubular hydraulic and oncotic pressures
   - the peritubular oncotic pressure varies directly with the filtration fraction, the GFR/RPF ratio
   - this ratio increases as most mediators of renal vessel constriction affect both afferent and efferent aa.
   - these physical factors affect reabsorption only in the PT where large diffusional fluxes occur, and are probably only important in large alterations of ECF volume

2. distribution of RBF
   - nephrons are not a homogeneous population, redistribution of flow to postulated "high-reabsorption" nephrons would affect Na⁺ balance

3. direct tubular effects of catecholamines
   - renal SNS tone and circulating adrenaline have direct action on tubular cells enhancing Na⁺ reabsorption, definitely in the PT, & others

4. direct tubular effects of angiotensin II
   - same c.f. CA's, in addition to stimulation of aldosterone and its intrarenal vascular effects, has direct effect on tubular cells enhancing reabsorption
   - also like the CA's, the effect is seen in the PT but ? other segments

e. other humoral agents
   - cortisol, oestrogen, growth hormone, and insulin enhance reabsorption
   - parathyroid hormone, progesterone, and glucagon decrease reabsorption

Summary of Sodium Regulation

- control of Na⁺ excretion is via GFR and Na⁺ reabsorption
- the later is controlled principally by the renin-angiotensin-aldosterone system but also by the SNS
- SNS activity is important in,
  - i. control of [aldosterone] via renin-angiotensin
  - ii. determination of intrarenal vascular factors & GFR
  - iii. direct action on tubular function
- despite these functions, the denervated kidney maintains Na⁺ balance
- reflexes that control these inputs are BP-regulating and initiated most often by changes in arterial ± venous pressure
- CVS function depends on plasma volume, which is a component of ECF volume, the later reflecting the mass of Na⁺ in the body
- these reflex systems maintain Na⁺ balance within 2% in normal individuals despite marked variations in intake and loss
Hyponatraemias

**Def’n:** plasma Na⁺ < 136 mmol/l

- determined by TBW, TBNa⁺, and TBK⁺
- ie. this is a whole body water derangement
- more commonly water excess, less often Na⁺ deficit

1. *iso-osmotic* (factitious)
   i. hyperlipidaemia - usually only when plasma TG’s > 50 mmol/l
   ii. hyperproteinaemia - multiple myeloma
   iii. IVT arm sample
   - plasma water ~ 93% of plasma volume
   - therefore increases in plasma solids will lower [Na⁺] pl factitiously
   - osmolality is unaffected → no Rx required
   - actual [Na⁺] = [Na⁺] pl x (measured osmolality)/(calculated osmolality)

2. *hyper-osmotic* → ↑ osmolar gap
   i. hyperglycaemia ↓ [Na⁺] ~ 1 mmol / 3 mmol ↑ BSL
   ii. mannitol, glycine, glycerol, urea
   iii. other solutes not entering cells
   - water is drawn into the ECF from the ICF
   - total body Na⁺ may be normal or depleted

3. *hypo-osmotic*
   i. **hypovolaemic** → persistent ADH effect
   - extrarenal losses - GIT, vomiting / diarrhoea
   - 3rd space
   - renal losses - Addison's disease
   - diuretics, osmotic diuresis
   - salt losing nephritis
   - hypo-aldosteronism
   - heparin (aldosterone suppression)
   - fluid replacement deficient in Na⁺
   ii. **slightly hypervolaemic** → fluid excess ~ 3-4 l, no oedema
   - SIADH, reset osmostat
   - severe hypothyroidism
   - psychogenic polydipsia
   - inappropriate IV fluids, eg. CRF
   iii. **hypervolaemic** → fluid excess > ~ 10 l, with oedema
   - CCF
   - nephrotic syndrome
   - 2° hyperaldosterone states
   - cirrhosis
   - renal failure
Diagnosis

a. physical examination
   - oedema
   - volume status

b. plasma biochemistry
   - U&E's
   - glucose
   - osmolality (measured & calc)

c. urinary $[\text{Na}^+]$
   i. $[\text{Na}^+]_u < 20$ mmol/l
      - extrarenal losses with normal renal function
      - $[\text{Cl}^-]_u$ usually parallels $[\text{Na}^+]_u$ except in RTA and hypovolaemia,
        where $\text{HCO}_3^-$ losses are high and $[\text{Cl}^-]_u$ low
      - 2° hyperaldosteronism, with a low effective circulating blood volume
   ii. $[\text{Na}^+]_u > 20$ mmol/l
      - states where there is renal wasting of sodium
      - Addison's, diuretics, ARF, CRF, SIADH

d. water challenge
   - giving a patient a water load will differentiate between,
   i. SIADH $\rightarrow$ reducing $[\text{Na}^+]$ further
   ii. reset osmostat $\rightarrow$ being able to excrete the load
      - obviously if hyponatraemia is severe this is contraindicated

e. saline infusion
   - will normalise those patients shedding $\text{Na}^+$ rich fluids and being replaced with low $\text{Na}^+$ fluids
Clinical Manifestations

- these depend upon both the extent of the derangement and the aetiology to a greater extent than the absolute [Na⁺]
- isotonic/factitious hyponatraemias cause little problem, eg. glycine 1.5% absorption during TURPS, etc.
- the use of agents such as glycine, which do not alter tonicity, avoids the problems associated with water shifts across membranes
- however, they do not prevent problems associated with a low [Na⁺]_{ECF}

a. CNS - symptoms and signs are more severe with rapid falls in [Na⁺]_{pl} > 10% change
   i. confusion
   ii. decreased conscious level
   iii. coma/convulsions ≤ 120 mmol/l [Na⁺]_{pl} ≤ 50% mortality

   • NB: mortality ~ 50% where [Na⁺]_{pl} falls below 120 mmol/l within 24 hours

b. CVS
   i. increased QRS duration @ [Na⁺]_{pl} < 115 mmol/l
   ii. ST segment elevation @ [Na⁺]_{pl} < 115 mmol/l
   iii. VT/VF @ [Na⁺]_{pl} < 110 mmol/l
   iv. increase BP/HR with volume overload (unreliable)

c. neuromuscular
   i. muscle cramps
   ii. muscle fasciculations
   iii. neuromuscular irritability
**Treatment - Mild**

a. discontinuation of aetiological agent

b. fluid restriction - hypervolaemic (SIADH, reset osmostat)
   \[ \leq 15 \text{ ml/kg/d} \]

c. high protein, low CHO/fat diet reduces H₂O intake

d. normal saline - hypovolaemic
   - replacement at 0.3x*

e. demethychlortetracycline - produces "nephrogenic DI"
   \[ \rightarrow \text{blocks renal ADH effects} \]

f. underlying pathology

**Treatment - Severe**

a. ABC

b. IVT - initial ECF resuscitation should be with 0.9% NaCl
   - Na⁺ deficit calculated against TBW, viz.

   \[ \delta[Na^+]_{TBW} = \left( \frac{140-\left[Na^+\right]_{pl}}{140} \right) \times \text{Weight} \times 0.6 \]

   • although sodium is only in the ECF, total body osmolality must be corrected
   (except - * below)

c. hypertonic NaCl - 3.0-5.0%
   • the aim is to raise the \([Na^+]_{pl} \sim 2 \text{ mmol/l/hr}\)
   • rates greater than this are associated with central pontine myelinolysis
   • demyelination is mostly seen in alcoholics
   \[ \rightarrow \text{quadriplegia, bulbar & pseudobulbar signs} \]
   • may use 8.4% NaHCO₃ in an emergency
   • strong NaCl 29.2% (5 mmol/ml) may be used to bring plasma Na⁺ up to 120-130
   mmol/l range if,
   i. rapid development of severe hyponatraemia & CNS signs
   ii. failure of above therapy
   iii. complicated by fluid overload (CRF)

d. loop diuretics
   • help prevent fluid overload & pulmonary oedema
   • may exacerbate hyponatraemia
   • some suggest mannitol is better

e. dialysis
Hypernatraemias

*NB:* these are always associated with *increased osmolality*

### Classification

- **hypovolaemic** → $\text{H}_2\text{O} \text{ loss} > \text{Na}^+$
  - most fluid losses have a $[\text{Na}^+]$ lower than plasma
  - therefore there is a net loss of water greater than $\text{Na}^+

  
  - 
    - i. renal
      - diuretics
      - glycosuria
      - ARF/CRF
      - partial obstruction
    
    - ii. GIT losses
      - diarrhoea, vomiting, fistulae
      - 3$^{\text{rd}}$ space losses
    
    - iii. respiratory losses
      - IPPV with dry gases
    
    - iv. skin losses
      - fever
      - ambient temperature
      - thyrotoxicosis

- (i) $[\text{Na}^+]_\text{U}$ increases / $U_{\text{osm}}$ decreases

- (ii-iv) $[\text{Na}^+]_\text{U}$ decreases / $U_{\text{osm}}$ increases

ie., with extrarenal losses there is renal compensation, the net effect is a decrease in $\text{ICF} > \text{ECF}$
b. \textit{iso} \rightarrow \textit{hypovolaemic}

- these result from pure water loss
- 67\% of TBW resides in the ICF
- dehydration increases plasma osmotic pressure, tending to maintain intravascular volume
- thus these patients do not become \textit{hypotensive} until $[\text{Na}^+]_{pl} \geq 160$-$170$ mmol/l
- therefore, this group are sometimes called "isovolaemic"

i. inadequate water replacement
   - iatrogenic
   - inadequate IVT
   - unconsciousness

ii. reset osmostat

iii. central diabetes insipidus
   - head injuries
   - post-surgical

iv. nephrogenic DI
   - 1\° = congenital renal resistance to ADH
   - 2\° = hypokalaemia
     - hypercalcaemia
     - lithium
     - methoxyflurane
   - produces a mild-moderate decrease in both ECF & ICF

c. \textit{iso} \rightarrow \textit{hypervolaemic} \rightarrow \text{Na}^+ \text{ gain} > \text{H}_2\text{O} \text{ gain}

- usually not sufficient $\text{H}_2\text{O}$ gain to produce oedema

i. iatrogenic
   - the major cause
     - $\text{NaHCO}_3$
     - feeding formulae, TPN
     - drinking sea water
     - exogenous steroids

ii. mineralocorticoid excess
   - Conn's syndrome
   - Cushing's disease / syndrome

- the later group usually have 1-3 l of excess TBW
- plasma Na$^+$ is usually normal to high, with associated \textit{hypokalaemic alkalosis}
- the increased plasma osmolality increases ADH secretion, which in turn increases ECFV, with subsequent \textit{renal escape} (see over)
- oedema in this group is therefore \textit{rare}
- ECFV is generally increased while ICFV decreases
■ **Secondary Hyperaldosteronism**

- characterised by persistent Na⁺ retaining reflexes, (decreased GFR, increased aldosterone, etc.), despite progressive overexpansion of the ECF and the development of oedema
- increased aldosterone is secondary to elevated renin via reflex control
- eg. cirrhosis of the liver, congestive cardiac failure, nephrotic syndrome

■ **Primary Hyperaldosteronism**

- Na⁺ retention does occur initially but after several days renal escape occurs and Na⁺ balance returns to normal
- elevated ECF volume initiates Na⁺ losing responses → increased ANF, increased GFR etc.
- the net effect of which is to deliver an increased load of Na⁺ to the collecting ducts, beyond their reabsorptive capability, thereby increasing excretion

  **NB:** that is, persistent Na⁺ retention cannot be initiated by an abnormality of only one of the pathways controlling balance

■ **Diagnosis**

a. history & examination
b. plasma biochemistry
c. urinary [Na⁺] & urinary osmolality
d. water deprivation challenge
e. administration of desmopressin

■ **Clinical Manifestations**

  **NB:** as for hyponatraemia, these depend more upon the rate of change, rather than the absolute change

a. **CNS**
   i. confusion
      - membrane irritability
      - brain shrinkage
   ii. decreased LOC
      - haemorrhage, venous thrombosis
      - spasticity, convulsions
   iii. coma
      - generally only seen [Na⁺]₀ ≤ 160 mmol/l
      - acute mortality
         - children ~ 40%
         - adults ~ 70%
      - chronic mortality
         - children ~ 10%
         - adults ~ 60%
b. **CVS**
   i. decreased contractility $\propto [\text{Ca}^{++}]/[\text{Na}^+]^2$
   ii. CCF $\propto$ volume overload

c. **other**
   - loss of weight
   - increased plasma Na$^+$
   - increased serum osmolality
   - thirst

### Treatment - Severe

a. ABC
b. Hartman's solution
   - slightly hypo-osmolar ~ 260 mosmol/l
   - resuscitation if hypotensive
c. 0.45% saline
   - use for replacement of H$_2$O/Na$^+$ deficit
   - aim to replace deficit in 24-48 hrs
   - ~ 2.0 mmol/l/hr rate of reduction

\[
H_2O_{(deficit)} \approx \left( \frac{[\text{Na}^+]_P - 140}{140} \right) \times \text{Weight} \times 0.6
\]

d. diuretics
   - for Na$^+$ excess
e. dialysis
   - for Na$^+$ excess
f. 5% dextrose
   - for H$_2$O losses in Na$^+$ excess
g. cease aetiological drugs
h. decrease Na$^+$ intake

### Treatment - Mild

a. cease/decrease Na$^+$ intake
b. cease aetiological drugs
c. IVT
   - 5% dextrose, dextrose/saline, 0.45% saline
d. DDAVP
   - for central DI
Osmolar Gap

**Def’n:** = the difference between the measured and calculated osmolality

\[ \leq 10 \text{ mmol/l normally, but may be up to 24 mmol/l} \]

**Calculated Osmolality**

\[ \sim 1.86 \times ([\text{Na}^+] + [\text{K}^+] + [\text{urea}] + [\text{glu}]) \text{ mmol/l} \]

\[ \sim 272-283 \text{ mmol/l normal range} \]

**Measured Osmolality**

\[ = \text{osmometer freezing point depression} \]

\[ \sim 0.001865^\circ C / \text{mmol} \]

\[ \sim 285-295 \text{ mmol/l normal range} \]

**NB:** some suggest using a value of 2 x [Na⁺], as the *osmotic coefficient* of 0.93 and the percentage of plasma water ~ 93% cancel out

- thus, hyperosmolar states may exist despite a normal or low [Na⁺]
- OG increases due to an increase in *unmeasured* osmotically active particles,
  a. alcohols - ethanol, methanol
    - mannitol
    - sorbitol, propylene glycol
  b. hyperlipidaemia
  c. hyperproteinaemia - multiple myeloma
  d. glycine

- these particles fall into one of two groups,
  a. *impermeate* solutes \( \rightarrow \) hypertonic state
    - eg., mannitol
  b. *permeate* solutes \( \rightarrow \) isotonic states
    - eg., urea

- acute changes are more important than chronic

**NB:** *hyperosmolality per se* may decrease *insulin* release, therefore raising the BSL and establishing a vicious cycle

- thus, some patients with *non-ketotic hyperosmolar coma* may not require insulin once the plasma glucose is normalised
- with substances which affect *tonicity*, eg. mannitol,
  a. the reduction in ICFV may result in cellular shrinkage, with confusion and coma
  b. reciprocal expansion of the ECFV may result in CCF

- providing renal function is normal, the ECFV may also decreased due to the subsequent *osmotic diuresis*
POTASSIUM

i. alkaline elemental metal
ii. atomic number = 19
iii. molecular weight ~ 39
iv. monovalent cation = the principal intracellular cation

• total body content ~ 55 mmol/kg, (3,850 mmol/70kg), distributed as follows,
  a. exchangeable ~ 90%
  b. ICF ~ 98%
  c. ECF ~ 2%
  d. bone & brain ~ 10%

• daily requirement ~ 0.5-1.5 mmol/kg/d (35-105 mmol/d/70kg)
• concentration ranges vary between tissues,
  a. plasma ~ 3.2-4.8 mmol/l (highly variable)
     ~ linear, semi-log relationship to TBK*
  b. ICF ~ 150 mmol/l
  c. gastric secretion ~ 10 mmol/l
  d. sweat ~ 10 mmol/l
  e. SI, bile & pancreatic ~ 5 mmol/l
  f. diarrhoea ~ 40 mmol/l

■ Daily Balance

a. intake ~ 70-100 mmol/d
   • GIT absorption passive down to luminal [K+] ~ 5-6 mmol/l
   • the majority of ingested K⁺ is therefore absorbed

b. losses ~ 0.7 mmol/kg/day obligatory
   i. renal ~ 60-90 mmol/d
      • GFR → ~ 720 mmol/day
      • virtually all K⁺ is reabsorbed by distal tubule
      • secretion along late DT & CT → 5-15% of filtered load
   ii. faeces ~ 10-20 mmol/d
      • this can increase greatly with diarrhoea or other SI losses
      • usual [K⁺] ~ 30 mmol/l
      • secretory lesions may also increase losses
Assessment of Potassium Status

a. plasma \([K^+]\)
   - difficult to assess, as ECF is only ~2% of body mass
   - however, if \([K^+]_{PL}\) is low and the pH is normal,
     there is a substantial total body deficit of \(K^+\)
   - a \([K^+]_{PL} < 3.0\ \text{mmol/l}\) usually represents a total deficit > 200-300 mmol/70kg
   - hyperkalaemia may, or may not represent an excess body \(K^+\)
   - \([K^+]_{PL}\) is most important in the short term due to the effects of \(K^+\) on transmembrane potentials

b. radioactive isotope dilution \(^{42}K^+\)
   - requires 24 hours distribution and several inaccuracies

c. urinary \([K^+]\)
   - not very useful due to the limited ability of the kidney to conserve potassium
   - a \([K^+]_{U} > 40\ \text{mmol/l}\) is suggestive of hyperaldosteronism

d. ICF \([K^+]\)
   - RBC, WBC and muscle
   - subject to artefacts from preparation
   - only really useful for research purposes

e. ECG - useful for monitoring acute changes only

Regulation of ECF Potassium Concentration

- ~98% of total body \(K^+\) is intracellular due to the action of the membrane bound \(Na^+/K^+\)-ATPase
- thus, the ECF \([K^+]\) is a function of 2 variables,
  a. total body \(K^+\)
  b. ECF/ICF distribution

- due to relatively small extracellular component, even small shifts in internal balance can markedly alter the extracellular \([K^+]\)
- such shifts are under physiological control, particularly in muscle & liver, and these offset alterations of extracellular \([K^+]\)
• major factors in this control are,
  1. \textit{adrenaline}
      • results in a net movement of $K^+$ into cells
      • mediated by $\beta_2$-adrenergic receptors
      • predominantly \textit{muscle & liver}
      • important during exercise and major trauma
  2. \textit{insulin}
      • at physiological concentration, insulin exerts a tonic permissive effect
      • promotes entry into muscle, liver and other tissues
      • more importantly, elevated plasma [$K^+$] stimulates insulin release, promoting its
        own entry into cells
  3. \textit{glucagon}
      • counteracts the effects of insulin tending to raise the plasma $K^+$
      • however, also increases $K^+$ secretion in the late DT & CT
  4. \textit{aldosterone}
      • the main site of action is the DT of the nephron
      • increases secretion, ? independent of $Na^+$
      • facilitates net movement of $K^+$ into cells, esp. with chronic elevated total body $K^+$
      • this is independent of renal handling of $K^+$

\textit{NB:} other factors that affect the balance of internal $K^+$ are not linked to homeostasis of
the internal environment but do affect $K^+$ significantly, of these \textit{plasma [H$^+$]} is the
most important

\section*{Potential Control Mechanisms}

1. acid-base status
2. $Na^+/K^+$-ATP'ase
3. Gibbs-Donnan effect
4. non-absorbable anions in the urine
5. diuretics
6. ECF volume & its effects on urine output
7. intestinal secretion
Functions

a. total body osmolality
   - total body osmolality is related to the total exchangeable Na\(^+\) & K\(^+\) and TBW
   - changes in either total body Na\(^+\)\(_E\) or K\(^+\)\(_E\) may result in changes in plasma osmolality, viz.
     \[ [\text{Na}^+]_{\text{pl}} \sim \frac{\text{Na}^+\_E + \text{K}^+\_E}{\text{TBW}} \]

b. resting membrane potentials
   - the [K\(^+\)]\(_{ECF}\) is closely regulated due to the primary importance of K\(^+\) in neuromuscular excitability
   - the resting membrane potential being predominantly determined as follows
     \[ E_M = -61.5 \log \frac{[K^+]_o}{[K^+]_i} \]
     thus,
     i. increasing [K\(^+\)]\(_o\) \to decreases \(E_m\)
     ii. decreasing [K\(^+\)]\(_o\) \to increases \(E_m\)
        - changes in ICF [K\(^+\)] having only a small effect
        - acute changes having a greater effect than chronic, as with the latter both ECF & ICF levels are likely to move in the same direction

c. influences action potentials in excitable tissues
   i. neural
   ii. cardiac
   iii. smooth & skeletal muscle

d. intracellular osmotic pressure and electroneutrality

e. protein synthesis \sim 1 \text{ mmol/g of protein intake}
Basic Renal Mechanisms

- $K^+$ is freely filterable at the glomerulus, though, the urine [$K^+$] may be slightly less than plasma due to a Donnan effect
- final urinary [$K^+$] represents only $\sim 10\text{-}15\%$ of the filtered fraction
- therefore, tubular reabsorption predominates, but it can be demonstrated under certain conditions that the tubules actively secrete $K^+$
- $K^+$ handling shows heterogeneity between short & long looped nephrons
- $\sim 50\%$ the filtered mass is reabsorbed in the convoluted PT
- this is primarily a passive process, driven by the electrochemical gradient created by water reabsorption but also by solvent drag
- in the pars recta of the PT and DLH, $K^+$ secretion occurs primarily by diffusion due to the high interstitial [$K^+$], in the medulla
- in the ALH, passive reabsorption is again the dominant process
- this is so effective in short-looped nephrons that the amount of $K^+$ entering the DT is only $\sim 10\%$ of filtered mass
- therefore, in short-looped nephrons, the PT reabsorbs 50% and the ALH another 40% plus the mass secreted into the pars recta and DLH
- long-looped nephrons also show reabsorption in the ALH but the quantity is unknown, certainly $<40\%$
- the early DT plays little if any role in $K^+$ handling

**NB:** the late DT and cortical CT are able to both reabsorb and secrete $K^+$, both processes being active (see below)

- the medullary CT usually manifests net reabsorption, this $K^+$ providing the high [$K^+$], driving diffusion into the straight PT and DLH
- therefore, there is a recycling of $K^+$ from distal to proximal tubular segments analagous to that described for urea

Important Generalisations

- the transport processes in the PT and loop are relatively unchanged by increases or decreases in total body $K^+$
- thus, the total mass of $K^+$ delivered to the DT is always a small fraction of the filtered mass
- physiological regulation of $K^+$ excretion is achieved mainly by altering $K^+$ transport in the DT and cortical CT and the major process regulated in these tubules is the rate of $K^+$ secretion
- the effects on $K^+$ excretion mediated by the DT and cortical CT are so great that the effects of changes in the filtered load (GFR x [$K^+$]$_{pl}$) may be ignored

Exceptions

- under certain conditions, reabsorption in the PT and ALH may be decreased and the delivery of a large quantity of $K^+$ to the distal site may overwhelm reabsorptive processes, these include,
  1. osmotic diuretics
  2. loop diuretics
  3. uncontrolled diabetes etc.
**Mechanism of Distal Potassium Secretion**

- the critical event is the *active* entry of K⁺ from the interstitium, via the basolateral membrane Na⁺/K⁺-ATPase, providing a high intracellular [K⁺]
- backward diffusion is far less than diffusion into the lumen due to the low gK⁺ of the basolateral membrane (see Renal Notes)
- the concentration gradient is opposed by the luminal membrane potential, $E_L \sim 30$ mV, cell (-)ve, however, the overall $\delta[EC]$ favours secretion
- in addition to basolateral gK⁺ being lower, the $E_{BL} \sim 80$ mV cell (-)ve, therefore, K⁺ pumped into cell favours net secretion
- the high luminal gK⁺ is due to the presence of specific K⁺-channels
- the presence of these channels accounts for DT secretion, c.f. PT which also has a high [K⁺] but low luminal gK⁺ and an unfavourable electrical gradient
- the ability of these segments to manifest reabsorption relies on the presence of an *active luminal pump*, (probably cotransport with Cl⁻)
- this pump is always operating, but at a low rate, and therefore opposes secretion, thus, when the activity of the basolateral pump is reduced, the tubule may show net reabsorption due to the unopposed action of the luminal pump
- this luminal pump may also be physiologically regulated, but this is far less significant than regulation of the basolateral Na⁺/K⁺-ATPase

*NB:* the fundamental step in secretion is the high intracellular [K⁺] created by the basolateral pump; passive luminal diffusion depends on,

i. the opposing luminal $E_M$
ii. luminal membrane gK⁺
iii. luminal [K⁺] gradient

**Homeostatic Control Of Distal Secretion**

- cells of the *adrenal cortex* are sensitive to ?extracellular [K⁺], more likely their internal [K⁺]
- increases in [K⁺] increase the secretion of *aldosterone* which acts on the distal segments by,
  a. increasing the activity of the basolateral Na⁺/K⁺-pump
  b. increasing the luminal permeability to K⁺
- the former of these effects is coincident with aldosterone's action enhancing Na⁺ reabsorption in the same segments
- the increased K⁺ secretion induced by these changes occurs quite rapidly
- if plasma [K⁺] remains high for several days, potassium *adaptation* occurs and the ability of the distal segments to secrete K⁺ is markedly increased
- mainly as a result of an increased number of basal pumps (? & luminal channels)
- low plasma [K⁺] has the directly opposite effects

*NB:* K⁺ secretion is not the only factor governed by aldosterone secretion, Na⁺ and H⁺ also being influenced by aldosterone
Other Factors Influencing Potassium Homeostasis

- K⁺ balance is affected by a large number of factors not designed to maintain homeostasis
- most important are the plasma [H⁺] and altered renal Na⁺ handling, especially due to diuretics

1. acid-base balance
   - the existence of an alkalosis, either metabolic or respiratory in origin enhances K⁺ excretion
   - these stimulatory effects appear to be mediated, at least in part through an increased [K⁺] in distal tubular cells, alkalosis stimulating the basolateral entry of K⁺
   - further, distal K⁺ reabsorption may be inhibited by alkalosis, the distal luminal pump requiring co-transport with Cl⁻ which is reduced in alkalosis

- respiratory acidosis and certain types of metabolic acidosis do tend to cause the opposite effects but only in the acute stages (< 24 hrs)
- in other forms of metabolic acidosis other factors enhance K⁺ excretion
- even those forms that have an acute phase of K⁺ retention, ultimately come to manifest increased K⁺ excretion

2. renal sodium handling
   - K⁺ excretion is virtually always found to be enhanced when urinary Na⁺ excretion is increased in the following situations,
     i. high NaCl dietary intake
     ii. saline infusion
     iii. osmotic diuresis
     iv. loop diuresis
   - increased excretion is due to enhanced distal tubular secretion, although there is some contribution of reduced PT reabsorption
   - all of these situations lead to an increased volume of fluid flowing through the distal segments, thereby reducing the rise in the luminal [K⁺] and enhancing diffusion from the tubule
   - these effects are not seen with a water diuresis with a low ADH, as the site of action of ADH is largely distal to the sites of K⁺ secretion

- similarly a reduced flow of fluid in the distal segments tends to inhibit K⁺ secretion
- further, in low flow states, luminal [Na⁺] becomes very low and causes the membrane to become hyperpolarised (cell more negative c.f. lumen)
- despite this tendency, in salt depletion and the diseases of secondary aldosteronism with oedema, K⁺ secretion may be relatively unchanged due to the stimulatory effect of aldosterone

NB: these later conditions generally manifest normal rates of K⁺ excretion, in contrast to primary aldosteronism where the elevated aldosterone and normal delivery of fluid to distal segments leads to severe K⁺ depletion
Hypokalaemia

**Def'n:**
- serum \([K^+]\) < 3.5 mmol/l
- plasma \([K^+]\) < 3.0 mmol/l

## Causes

a. **decreased intake**
   - NBM

b. **increased losses - renal**
   i. **tubular disorders**
      - RTA
      - leukaemia
      - Liddle's syndrome
      - increased DT flow
   ii. **mineralocorticoid excess**
      - primary aldosteronism
      - secondary aldosteronism
      - cirrhosis, nephrotic syndrome, CCF
      - Barter's, JGA cell tumour, malignant ↑ BP
      - glucocorticoid excess
      - Cushing's, ectopic ACTH, iatrogenic
   iii. **diuretics**
      - PT agents
      - loop diuretics
      - early DT
      - thiazides
   iv. **other drugs**
      - amphotericin B
      - anionic drugs, eg. penicillins, other antibiotics
   v. **hypomagnesaemia**
   vi. **metabolic alkalosis**

c. **increased losses - GIT**
   - diarrhoea, fistulae
   - malabsorption syndromes
   - vomiting

d. **increased losses - skin**
   - extreme sweating (rarely)

e. **compartmental shifts**
   i. **alkalaemia**
      \[
      \uparrow \text{pH} \sim 0.1 \\
      \downarrow [K^+]_{pl} \sim 0.5 \text{ mmol/l}
      \]
   ii. **insulin**
   iii. \(\text{Na}^+/\text{K}^+\)-ATP'ase stimulation
      - \(\beta_2\)-sympathomimetics
      - salbutamol, adrenaline
      - methylxanthines
   iv. familial periodic paralysis
   v. **hypomagnesaemia**
   vi. **barium poisoning**
## Manifestations

### a. CVS
   i. electrophysiology
      • $E_m$ more negative at $[K^+] \leq 3.0$ mmol/l
      • APD is **increased** significantly
      • the following are slightly increased - $\delta V/\delta t_{\text{max}}$ phase 0
        - ERF
        - threshold potential
        - phase 4 depolarisation
        - conduction velocity $v_c$
   ii. ECG
        - depression of ST segments
        - depression/inversion of T waves
        + U waves $\rightarrow$ "apparent" long QT
   iii. dysrhythmias
        - VEB's, VT / VF
        * $\uparrow \uparrow$ sensitivity to *digoxin* & *hypercalcaemia*
        * severe depletion $\rightarrow$ arrest in VF or systole
   iv. chronic depletion $\rightarrow$ **subendocardial necrosis**

### b. neuromuscular
   i. increased sensitivity to NDMR's
      $\propto$ increase of resting $E_m$
   ii. muscle weakness / paralysis
      $\propto$ severe depletion
   iii. chronic depletion
      $\rightarrow$ **rhabdomyolysis**

### c. renal
   i. nephrogenic DI
      $\propto$ resistance to ADH
   ii. increased ammonia production

### d. endocrinological
   • decreased insulin release
   • $\downarrow [K^+] \leq 2.5$ mmol/l $\rightarrow$ $\uparrow$ BSL $\leq 20$ mmol/l

### e. acid-base balance
   • allegedly hypokalaemia leads to a **metabolic alkalosis**, due to an $\uparrow$ ICF $[H^+]$
   • however, most hypokalaemia states coexist with NaCl deficits, and it is the CI *deficit* which produces the metabolic alkalosis
   • severe hypokalaemia leads to **ADH resistance** and a form of nephrogenic DI
   • the subsequent *volume depletion* $\rightarrow$ a metabolic alkalosis
   • hypokalaemia and a **metabolic acidosis** may occur in,
   i. patients on carbonic anhydrase inhibitors
   ii. RTA
   iii. extra-renal $HCO_3^-$ & $K^+$ losses - diarrhoeas, fistulae
   iv. partially treated DKA

### f. GIT
   • severe hypokalaemia may lead to intestinal *ileus*
**Treatment - Severe**

a. ABC
b. KCl $\leq 0.5$ mmol/kg/d *with* ECG monitoring
   $\leq 0.25$ mmol/kg/d *without* ECG monitoring
c. replace Mg$^{++}$ deficit

**Treatment - Mild**

a. cease aetiological agent
b. KCl - orally $\sim 1$ mmol/kg/d
c. replace Mg$^{++}$ deficit
d. K$^+$ sparing diuretics

**Hypokalaemia & Alkalosis**

- if the hypokalaemia is associated with hypovolaemic/hypochloraemic alkalosis, then this will not be corrected until the Cl$^-$ deficit is replaced
- this results from a deficiency of absorbable anion in the renal tubules
- in response the kidney synthesises more HCO$_3^-$ to match Na$^+$ in the ECF, secreting more H$^+$ and K$^+$ into the tubules

*NB:* some argue hypokalaemia *per se* will *not* generate an alkalosis, but that it will *maintain* an alkalosis, once generated
Hyperkalaemia

**Def'n:** serum [K⁺] > 5.5 mmol/l
plasma [K⁺] > 5.0 mmol/l

■ **Aetiology - 1**

**Def'n:** divide according to the *intake / output / distribution*

a. **increased intake**
   - rarely a problem, except with ↓drenal function
   - massive blood transfusion, IVT

b. **decreased losses**
   - renal
   i. renal failure
      - acute, or severe chronic
      - tubular disorders
   ii. mineralocorticoid deficiency
      - hypoaldosteronism, heparin
      - Addison's (see below)
   iii. decreased distal tubular flow / decreased distal NaCl delivery
   iv. potassium sparing diuretics
      - spironolactone, amiloride, triamterene
   v. other drugs
      - indomethacin, ACE inhibitors

c. **compartmental shifts**
   i. **acidaemia**
      - pH ~ 0.1 / ↑[K⁺] ~ 0.6 mmol/l
      - this effect is greater with non-organic acids (HCl), cf. organic acids (lactate)
      - this may be due to the fact that Cl⁻ is an obligatory ECF anion, the unaccompanied movement of H⁺ into the ECF forcing K⁺ from the cell
      - further, the half life for removal of lactate by the liver is shorter than excretion of H⁺ by the kidney
   ii. **mineralocorticoid deficiency**
      - Addison's disease, steroid withdrawal
      - hypoaldosteronism
      - plasma K⁺ is multifactorial
      - K⁺ₐₑᵣ → K⁺ᵢₑᵣ
      - decreased DT flow
      - decreased DT aldosterone effects
   iii. cellular damage
      - haemolysis, rhabdomyolysis, tumour lysis
      - severe burns, massive ischaemia, exercise
   iv. drugs
      - suxamethonium, arginine, β-blockers
      - fluoride toxicity, digitalis toxicity
   v. insulin deficiency
   vi. familial periodic paralysis
      - hyperkalaemic variant
   vii. hyperosmolality
      - the movement of water from cells increases the [K⁺]ᵢₑᵣ and the gradient for passive diffusion
      - seen with large doses of mannitol given rapidly (1.5-2.0 g/kg)
      - the hyperkalaemia of DKA is due to this effect in addition to the acidaemia
Aetiology - 2

Def'n:  divide according to the origin & time course

a. factitious
i. haemolysis, delayed analysis of sample
ii. EDTA contamination
iii. thrombocytosis > 750,000 / µl
iv. leukocytosis > 50,000 / µl
v. KCl administration / IVT arm sample

b. acute
i. excessive intake - IVT, massive transfusion
   - metabolic acidosis
   - drugs, drug O/D
   - low insulin states
   - familial periodic paralysis
ii. shift out of cells
iii. tissue damage - rhabdomyolysis, burns, MH, etc.

b. chronic
i. chronic renal failure - esp. with acidosis, anuria
ii. adrenal insufficiency - Addison's
   - heparin (aldosterone suppression)
iii. K⁺ sparing drugs - diuretics
   - ACE inhibitors
   - indomethacin
Aetiology - 3

Def'n: divide according to \( \text{HCO}_3^- \) & anion gap

a. high \( \text{HCO}_3^- \):
   - respiratory acidosis (do ABG's)

b. normal \( \text{HCO}_3^- \):
   i. factitious
      - thrombocytosis, leukocytosis
      - haemolysis, delayed analysis of sample
      - IVT arm sample, KCl administration
      - EDTA contamination
   ii. drugs
      - digoxin overdose
      - succinylcholine
      - cessation of β-agonists
      - fluoride
   iii. Addison's
      - \( * \) Na\(^+\)/K\(^+\) < 25:1
      - steroid withdrawal
   iv. hyperkalaemic periodic paralysis

c. low \( \text{HCO}_3^- \) & normal anion gap
   i. early CRF, ARF
      - check urea & creatinine
   ii. drugs / infusions
      - K\(^+\) sparing agents
         - spironolactone, amiloride, triamterene
         - captopril, enalapril
         - indomethacin
         - HCl infusion
         - arginine HCl
   iii. Addison's
      - or steroid withdrawal
   iv. massive transfusion
      - high K\(^+\)
      - hypovolaemia, haemolysis

d. low \( \text{HCO}_3^- \) & high anion gap acidosis
   i. CRF
      - U&E's
   ii. metabolic acidosis
      - lactate, ketones
      - exogenous acids (ethanol, methanol, aspirin)

   \( \rightarrow \) ↑[K\(^+\)] ~ 0.5 mmol / ↓pH ~ 0.1

   iii. tissue damage
      - rhabdomyolysis
      - burns, MH
   iv. drug overdose
      - methanol, ethylene glycol
      - paraldehyde, salicylates
Clinical Effects

a. CVS
   i. electrophysiology
      - decreased resting $V_m$, phase 0 $\delta V/\delta t_{max}$, $v_c$
      - decreased phase 4 depolarisation & automaticity
      - little alteration in threshold $V_t$
      - decreased APD & ERP
      - decreased contractility
   ii. ECG
      - peaked T-waves
      - widening of QRS "sine-wave"
      - loss of P-waves
      - increased PR interval
   iii. rhythm
      - effects are increased by decreased $[\text{Na}^+]_p/[\text{Ca}^{++}]_p$
      - atrial arrest
      - AV block
      - VT/VF occasionally precede arrest
      - severe elevation $\rightarrow$ arrest in diastole

b. CNS/NMJ
   - ascending weakness
   - cranial nerves affected last
   - decreased sensitivity to NDMR's ($2^\circ V_m$)

c. anaesthesia
   - impaired spontaneous ventilation
   - risk of suxamethonium hyperkalaemia
   - cardiac arrhythmias
   - increased toxicity of local anaesthetics

d. renal
   - alleged that the increase $[\text{K}^+]_p$ decreases renal $\text{H}^+$ excretion
   - there is no convincing evidence for this
Treatment - Hyperkalaemia > 6-7 mmol/l

a. ABC
b. look for ECG / muscle changes ± recheck level
c. hyperventilate (if intubated)
d. CaCl₂ 10% ~ 5-10 ml (≡ Ca++ ~ 3.4-6.8 mmol)
   ? Ca-gluconate better as not an acidifying salt
e. dextrose ~ 25g (50 ml/50%) +
   insulin ~ 10U IV
   • providing the BSL is near normal
   • onset is quick, maximum effect seen ~ 1 hr
f. NaHCO₃ ~ 50-100 mmol
   • onset of action is immediate, however duration is only 1 hr
   • NB: 100 mmol HCO₃⁻ → 2.24 l CO₂
g. if renal function normal - IV fluids
   - Frusemide 20 mg IV
h. if renal failure present - Resonium A 30g PR & NG
   - dialysis CVVHD

Treatment - Mild

a. cease aetiological agent
b. Resonium A
   • exchanges Na⁺ or Ca++ for K⁺
   • theoretically Ca++ exchange is better as there is less Na⁺ load and Ca++ counteracts
     the cardiac effects of hyperkalaemia
   • may be given orally or rectally
   • onset of effect not seen until ~ 1 hr
c. decrease intake
d. correct underlying problem - volume replacement
   - steroid replacement
ACID-BASE BALANCE

Definitions

**Acid:** a proton, or hydrogen ion donor

**Base:** a proton, or hydrogen ion receiver

**Plasma pH:** the negative log\(_{10}\) of the hydrogen ion activity  \(\equiv [H^{+}]\)

Normal pH = 7.4 ± 0.4 \(\equiv [H^{+}] \sim 39\) nmol/l

**Acidosis:** an abnormal process or condition which would lead to an acidaemia, if uncompensated

**Alkalosis:** an abnormal process or condition which would lead to an alkalaemia, if uncompensated

**Acidaemia:** a plasma pH \(\leq 7.36\)

**Alkalaemia:** a plasma pH \(\geq 7.44\)

**Respiratory:** a disorder where the primary disorder is a change in the \(P_{CO_2}\)

**Metabolic:** a disorder where the primary disturbance is in the plasma \([HCO_3^-]\)

**Base Excess:** the amount of strong acid (1 molar) required to be added to 1.0 l of, fully saturated blood, at 37°C, at \(P_{CO_2} = 40\) mmHg, to return the pH to 7.4

Normal BE = 0 ± 2.0 mmol/l

**Standard Bicarbonate:** the \(HCO_3^-\) concentration in fully saturated blood, when the \(P_{CO_2} = 40\) mmHg at 37°C (**a derived variable**)

Normal = 24.0 ± 2.0 mmol/l

**Plasma Bicarbonate:** the actual \(HCO_3^-\) concentration in plasma at that particular point in time; cannot be measured but is calculated from the Henderson-Hasselbalch equation, when the \(P_{CO_2}\) and pH are known

\[ \text{Total CO}_2 = [HCO_3^-] + [H_2CO_3] \]
\[ \sim 24.0 \pm 2.0\ \text{mmol/l} \]

\[ [H_2CO_3] \sim 1.2\ \text{mmol/l} \]

\[ \text{Anion Gap} = [Na^+] - (([Cl^-] + [HCO_3^-]) \sim 12.0 \pm 2.0 \]

or, \[ ([Na^+] + [K^+]) - ([Cl^-] + [HCO_3^-]) \sim 16.0 \pm 2.0 \]

NB: some laboratories report the plasma bicarbonate as the total \(CO_2\), where this is given by,
NB: when assessing blood gas analyses,

i. the BE and standard bicarbonate give the same information, ie. the non-respiratory component to the acid-base disturbance
ii. the actual bicarbonate does not give any additional information as it has been derived from the pH and P_{aCO2}

Sources of Acid

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount (mmol/d)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CO₂</td>
<td>~ 12,500</td>
<td>(R:12-20,000)</td>
</tr>
<tr>
<td>2. lactate</td>
<td>~ 1,500</td>
<td></td>
</tr>
<tr>
<td>3. HSO₄</td>
<td>~ 45</td>
<td></td>
</tr>
<tr>
<td>4. H₂PO₄</td>
<td>~ 13</td>
<td></td>
</tr>
<tr>
<td>5. other acids</td>
<td>~ 12</td>
<td></td>
</tr>
<tr>
<td>6. organic acids in disease</td>
<td>- eg. ketoacids</td>
<td></td>
</tr>
<tr>
<td>7. alkalising salts</td>
<td>- K⁺, lactate, acetate, citrate (little importance)</td>
<td></td>
</tr>
</tbody>
</table>

**CO₂**

- the principal acid product of metabolism is CO₂, equivalent to potential carbonic acid
- excreted by the lungs & doesn't contribute to the net gain of plasma H⁺

**Non-Volatile, Fixed Acids**

- includes sulphuric and phosphoric acids (generated from the catabolism of proteins and other organic molecules), lactic acid and keto-acids
- in normal "Western" diets the net daily production ~ 40-80 mmol
- in vegetarians there may be net production of alkali

**Gastrointestinal Secretions**

- vomitus may contain a large [H⁺]
- other GI secretions have a high [HCO₃⁻], therefore net loss = H⁺ gain

**Urine**

- the kidneys normally excrete the 40-80 mmol of fixed acids generated per day
- their H⁺ excretion is also regulated to account for
  a. any net excretion or retention of CO₂ by the lungs
  b. any alteration in metabolic generation of fixed acid
Body Response to Acid

1. **dilution** - weak

2. **buffering**
   - extracellular
     - HCO$_3^-$
     - protein (Hb, alb)
     - HPO$_4^{2-}$
   - intracellular
     - ~ 30 mmol/l protein
     - ~ 140 mmol/l HPO$_4^{2-}$
     - ~ 10 mmol/l HCO$_3^-$

   \[ \rightarrow \text{buffers} \approx 90\% \text{ of respiratory disorders} \]
   \[ \approx 60\% \text{ of metabolic acidosis} \]
   \[ \approx 30\% \text{ of metabolic alkalosis} \]

3. **exchange**
   - bone (Ca$^{2+}$)
   - ICF ions (K$^+$)
   \[ ? \text{PTH may play a role (phosphaturia & H$^+$ loss)} \]

4. **renal acid excretion**
   - PT
     - high capacity, low gradient system
     - ~ 200 mmol/hr
     - influenced by
       - ICF acidosis
       - hypokalaemia
       - $P_{\text{aco2}}$, luminal pH
       - functional ECF
       - reabsorbable anion (HCO$_3^-$)
       - carbonic anhydrase activity
       - PTH
   - DCT
     - low capacity, high gradient system
     - ~ 30 mmol/hr \[ \rightarrow \text{minimum achievable pH} \approx 4.5 \]
     - influenced by
       - ICF acidosis
       - hypokalaemia
       - luminal pH
       - mineralocorticoid activity

5. **pulmonary CO$_2$ excretion**
Buffering

Def’n: serum survival limits → pH ~ 6.7-8.5
extracellular fluids → pH ~ 7.35-7.45
→ [H⁺]int ~ 45 to 35 nmol/l

- the intracellular pH is difficult to determine and varies from one organelle to another, a mean value pHICF ~ 6.9
- the normal [CO₂] in body fluids is fixed at 1.2 mmol/l, which corresponds to a PaCO₂ ~ 40 mmHg
- the total buffer capacity of body fluids is ~ 15 mmol/kg body weight
- this is essential for preventing any large change from the normal [H⁺]int ~ 39 nmol/l
- the normal daily acid load of 40-80 mmol would cause a profound change in plasma pH
- because intracellular and extracellular buffers are functionally linked, the isohydric principal, measurement of the plasma bicarbonate system provides information about total body buffers
- the major intracellular buffers are proteins and phosphates
- these systems are in equilibrium and although 50-90% of buffering is intracellular, the assessment of HCO₃⁻ provides a reliable index
- from the dissociation of carbonic acid,

\[ \text{H}_2\text{CO}_3 \rightleftharpoons \text{HCO}_3^- + \text{H}^+ \]

\[ K_A = \frac{[\text{HCO}_3^-] \cdot [\text{H}^+]}{[\text{H}_2\text{CO}_3]} \] by the law of mass action

- but as \( K_A \) only applies to infinitely dilute solutions with negligible interionic forces, the apparent dissociation constant, \( K_A' \), is used
- this may be rewritten for hydrogen ion, viz.

\[ [\text{H}^+] = \frac{K_A' \times \alpha.P_{CO_2}}{[\text{HCO}_3^-]} \]

- \( K_A' \) cannot be derived and is determined experimentally by measuring all three variables under a wide range of physiological conditions
- under normal conditions, using mmHg → \( \alpha K_A' \sim 24 \)
- therefore, the equation may be written,

\[ [\text{H}^+] = \frac{24 \times P_{CO_2}}{[\text{HCO}_3^-]} \]

so,

\[ P_{CO_2} \propto [\text{HCO}_3^-] \cdot [\text{H}^+] \]

- as \([\text{H}_2\text{CO}_3]\) is always proportional to \([\text{CO}_2]\), which is proportional to \( P_{aCO_2} \) the equation may be written,

\[ pH = 6.1 + \log \frac{[\text{HCO}_3^-]}{0.0301 \times P_{aCO_2}} \]

Henderson-Hasselbalch Equation
• as is evident from the **Henderson-Hasselbalch** form of the equation, regulation of pH may be achieved by regulation of both CO₂ and HCO₃⁻
• the kidneys function by two processes,
  1. variable reabsorption of filtered HCO₃⁻
  2. addition of new HCO₃⁻ to renal plasma

• there are various methods of assessment of deviation from "normal" blood gas parameters,
  1. graphical plot of plasma [HCO₃⁻] vs. pH → Davenport diagram (West 6.8)
  2. graphical plot of log PCO₂ vs. pH → Siggaard-Andersen
  3. normogram of [HCO₃⁻]ₚl vs. PₐCO₂ → see Harrison's (preferred method)

■ **Bicarbonate Reabsorption**

**NB:** Filtered HCO₃⁻/d = GFR x [HCO₃⁻]ₚl (ie. freely filterable)
~ 180 l/d x 24 mmol/l
~ 4320 mmol/d

• reabsorption of HCO₃⁻ is a conservation process and essentially none appears in the urine
• excretion of this load of bicarbonate would be equivalent to adding over 4000 ml of 1M acid to the body!
• minimal **passive** reabsorption occurs for HCO₃⁻ because,
  a. luminal and basolateral **permeability** is low, c.f. Cl⁻
  b. **active transport** processes are dominant and eliminate δ[electrochemical]

• the mechanism for reabsorption of HCO₃⁻ involves secretion of H⁺ into the lumen
• this is generated within the cell from CO₂ and water by **carbonic anhydrase** (CA), the generated H⁺ destined for the lumen and the HCO₃⁻ entering the peritubular plasma by facilitated diffusion
• the luminal membrane also contains CA and filtered HCO₃⁻ combines with the secreted H⁺ and is converted to CO₂ and water which are free to diffuse into the tubular cell
• therefore, the filtered HCO₃⁻ does not itself enter peritubular plasma
• **H⁺ secretion** varies in different portions of the nephron,
  a. in the PT → counter-transport with Na⁺
  b. in the distal segments → primary luminal H⁺-ATPase pump

• these secreted H⁺ ions are **not** excreted in the urine, but are reabsorbed as H₂O and CO₂
• therefore they **do not** constitute acid excretion, as is the case for any H⁺ combining with HCO₃⁻
• the process of H⁺ secretion and HCO₃⁻ reabsorption occurs throughout the nephron with the exception of the **DLH**
• in the **PT** ~ 80-90% of filtered bicarbonate is reabsorbed, the remainder normally being reabsorbed in the ALH, DT and CT
• the presence of **luminal CA** in the PT accounts for very large quantities of carbonic acid formed
• the later segments lack luminal CA, therefore distal conversion of H₂CO₃ → CO₂ + H₂O occurs slowly and often after urine has left the nephron
• therefore urine PCO₂ may be **greater** than plasma under certain conditions
Renal Excretion of Acid

- this is synonymous with "addition of new bicarbonate to plasma"
- secreted H\(^+\) combining with luminal HCO\(_3\)\(^-\), effects HCO\(_3\)\(^-\) reabsorption, not acid excretion
- secreted H\(^+\) combining with urinary buffer is excreted in the urine and the generated HCO\(_3\)\(^-\) represents "new" bicarbonate entering the plasma
- only a very small quantity of H\(^+\) is in free solution in equilibrium with buffer
- the source of essentially all excreted H\(^+\) is tubular secretion, glomerular filtration makes no significant contribution (~ 0.1 mmol/d)
- the two most important urinary buffers are phosphate and ammonia
- the quantity of urinary buffer limits the rate at which the kidneys can excrete acid
- in the DT the minimum pH ~ 4.4, limited by inhibition of the luminal H\(^+\)-pump at low pH
- therefore, the quantity of buffer determines the mass of H\(^+\) which may be secreted before the limiting pH is reached

### Urinary Phosphate and Organic Buffers

- the relationship between monobasic and dibasic phosphate is as follows,

\[
\text{HPO}_4^{2-} + \text{H}^+ \leftrightarrow \text{H}_2\text{PO}_4^{-}
\]

\[
\text{pH} = 6.8 + \log \left( \frac{[\text{HPO}_4^{2-}]}{[\text{H}_2\text{PO}_4^-]} \right)
\]

- therefore, at pH = 7.4 the ratio of dibasic:monobasic ~ 4:1
- by the time the limiting pH of 4.4 is reached, the ratio ~ 1:250
- effectiveness as a buffer is limited by,
  a. protein binding slightly reduces the amount filtered
  b. only 80% of the filtered mass is in the dibasic form
  c. tubular reabsorption of \(\rightarrow \) ~ 75% of the filtered mass

\[
\rightarrow \text{end result is only } \sim 35-40 \text{ mmol/d is available for buffering secreted H}^+
\]

- normally, phosphate and ammonia are the only important buffers
- however, under abnormal conditions the urine may contain large quantities of anions of keto-acids, acetoacetate and \(\beta\)-hydroxybutyrate
- these appear as their tubular T\(_{\text{Max}}\)'s are exceeded
- however, they have only limited usefulness as buffers due to their low pK\(_a\)'s ~ 4.5
- therefore, only 1/2 of the excreted keto-acid anions are available to accept H\(^+\)
Urinary Ammonia Buffer

- the ammonia/ammonium reaction is as follows,

\[
\text{NH}_3 + \text{H}^+ \leftrightarrow \text{NH}_4^+
\]

\[
\text{pH} = 9.2 + \log \frac{[\text{NH}_3]}{[\text{NH}_4^+]}\]

- at pH = 7.4, the ratio will be ~ 1:63
- therefore, virtually all synthesised \(\text{NH}_3\) entering the lumen will immediately pick-up a \(\text{H}^+\) ion

NB: accordingly, as long as \(\text{NH}_3\) is available from the tubular cells, urinary acid excretion and addition of bicarbonate to the plasma can continue

Ammonia Synthesis & Diffusion Trapping

- glomerular filtration is not a significant source of \(\text{NH}_3\), as its combined \([\text{NH}_3/\text{NH}_4^+]\) is very low, and only \(~1.5\%\) of this is in the \(\text{NH}_3\) form
- the source of ammonia is synthesis in renal tubules from glutamine,

\[
\begin{align*}
\text{glutamine} & \rightarrow \text{glutamate} + \text{NH}_4^+ \\
\text{glutamate} & \rightarrow \alpha\text{-ketoglutarate} + \text{NH}_4^+ \\
\text{glycine} + \alpha\text{-ketoglutarate} & \rightarrow \text{glutamate} + \alpha\text{-keto-}acids
\end{align*}
\]

- the generation of \(\alpha\text{-ketoglutarate}\) also generates \(2\text{H}^+\), which has 3 possible fates,
  1. complete oxidation to \(\text{CO}_2\) and water
  2. gluconeogenesis
  3. recycling to glutamate (above)

- therefore, the generation of ammonia itself does not add \(\text{H}^+\) to the body
- prolonged acidosis \(\rightarrow\) adaptation of ammonia synthesis, involving enhanced transport of glutamine into the mitochondrion \(\pm\) increased glutaminase levels
- once synthesised, ammonia diffuses rapidly across the luminal membrane by non-ionic diffusion, or diffusion trapping
- in both cell and lumen the base/conjugate-acid pair are in equilibrium, the relative quantities of each being pH dependent
- due to the low pH of luminal fluid, almost all \(\text{NH}_3\) entering the tubule accepts a \(\text{H}^+\) ion, thereby maintaining a concentration gradient for the diffusion of \(\text{NH}_3\) from the cell
- ratio of \(\text{NH}_3/\text{NH}_4^+\) at pH = 4.4 \(\sim 1:63,000\)
- as the luminal membrane is virtually impermeable to ammonium, at low pH ammonia passively diffuses into the lumen and is trapped there by conversion to ammonium
- as long as ammonia synthesis can keep pace with acid secretion, tubular pH will not fall
- ammonium excretion can increase from the normal 20-30 mmol/d \(\rightarrow\) > 500 mmol/d
- in contrast, phosphate may only increase by \(~20\text{-}40\) mmol/d
conversely, if the urine pH is not low the luminal \([\text{NH}_3]\) will rise opposing any further diffusion and ammonium excretion will be low

ammonia is synthesised in both the PT and distal segments, however urine pH only falls significantly in the distal segments, therefore most ammonia synthesis and trapping occurs distally

some of the ammonia in the DT actually short-circuits the loop by diffusing from the PT and enters the CT from the medullary interstitium

Integration of Bicarbonate Reabsorption and Acid Excretion

- the fate of secreted \(\text{H}^+\) depends on whether it combines with \(\text{HCO}_3^-\) effecting its reabsorption, or with urinary buffer effecting acid secretion
- which of these two processes occurs is determined by,
  a. the mass of each buffer present
  b. the independent pK_a's of the conjugate pairs
  c. the luminal pH

- compared to \(\text{HCO}_3^-\), relatively little other buffer is present, therefore little non-bicarbonate buffer is titrated until almost all of the \(\text{HCO}_3^-\) is reabsorbed
- once the bicarbonate has been largely reabsorbed, most secreted \(\text{H}^+\) combines with urinary buffer
- ergo, the PT secretes a far greater mass of \(\text{H}^+\) than the distal segments, however this effects bicarbonate reabsorption and the luminal pH falls < 1 unit, only a small amount of \(\text{H}^+\) being picked-up by phosphate etc.
- in contrast, the DT the \([\text{HCO}_3^-]\) is low and secreted \(\text{H}^+\) is sufficient to effect its reabsorption plus lower the pH allowing titration of other buffers and trapping of ammonia
- however, should a large quantity of bicarbonate reach the distal segments, most secreted \(\text{H}^+\) would be expended in bicarbonate reabsorption rather than in titration of urinary buffer

Homeostatic Control of Tubular Acid Excretion

1. glomerulotubular balance
   - for bicarbonate = the same phenomenon as seen with \(\text{Na}^+\) reabsorption,
     \[\text{H}^+\] secretion & \(\text{HCO}_3^-\) reabsorption varies directly with GFR
   - ie., if GFR increases 25%, bicarbonate reabsorption increases by a similar amount
   - prevents large alterations of acid/base balance with changes in GFR

2. \(P_{\text{aco2}}\) and renal intracellular pH
   - the single most important determinant renal \(\text{H}^+\) secretion is the \(P_{\text{aco2}}\)
   - in the physiological range, \(P_{\text{aco2}}\) lies on "shoulder" of curve (??linear)
   - renal tubular cells respond directly to the \(P_{\text{co2}}\) of perfusing blood
   - \(\text{CO}_2\) raises the intracellular \([\text{H}^+]\) by mass action and this increases the rate of \(\text{H}^+\) secretion and increases the number of luminal H-pumps
   - intracellular pH is more dependent on \(P_{\text{aco2}}\) than arterial pH due to the low membrane permeability to \(\text{H}^+\) and \(\text{HCO}_3^-\)
Respiratory Acidosis and Alkalosis

\[
\text{CO}_2 + \text{H}_2\text{O} \leftrightarrow \text{H}_2\text{CO}_3 \leftrightarrow \text{HCO}_3^- + \text{H}^+
\]

\[
K_A = \frac{[\text{HCO}_3^-] \times [\text{H}^+]}{[\text{H}_2\text{CO}_3]} \quad \text{by the law of mass action}
\]

- but as \( K_A \) only applies to infinitely dilute solutions with negligible interionic forces, the \textit{apparent dissociation constant}, \( K_A' \), is used
- \( \text{CO}_2 \) can be used instead of \( \text{H}_2\text{CO}_3 \) because their concentrations are always in direct proportion
- this may be rewritten for hydrogen ion, viz.

\[
[H^+] = \frac{K_A' \times \alpha P_{\text{CO}_2}}{[\text{HCO}_3^-]}
\]

- in respiratory insufficiency the reaction is shifted to the right, with resulting acidosis
- bicarbonate increases but not to the same degree as \( \text{CO}_2 \), as \([\text{H}^+] \times [\text{HCO}_3^-] = K_A' \times [\text{CO}_2] \)

\textit{NB:} increases in \( P_{\text{CO}_2} \) increase the \textit{product} of \([\text{H}^+] \times [\text{HCO}_3^-] \)

- \( \text{pH} \) is restored by elevating \( [\text{HCO}_3^-] \) to the same degree as \( [\text{CO}_2] \)
- increased \( P_{\text{CO}_2} \) stimulates tubular \( \text{H}^+ \) secretion, which reabsorbs all the filtered bicarbonate and additional "new" bicarbonate is added to the blood by the formation of titratable acid and ammonium
- this continues to a new steady-state point where the elevated \( \text{H}^+ \) secretion can only serve to reabsorb the increased filtered load of \( \text{HCO}_3^- \)
- the sequence of events for alkalosis is the direct opposite

\textit{NB:} renal compensation is not perfect, \([\text{HCO}_3^-]\) is not elevated to the same degree as \([\text{CO}_2]\)
Metabolic Acidosis and Alkalosis

**Metabolic Acidosis**

- caused by the primary addition, or loss of either acid or alkali to the body
- e.g. either loss of $\text{HCO}_3^-$ or addition of $\text{H}^+$ ions will lower both the plasma $[\text{HCO}_3^-]$ and pH
- the kidneys compensate by increasing $\text{H}^+$ ion secretion, thereby raising the plasma $[\text{HCO}_3^-]$ and restoring the pH
- this occurs in the absence of any apparent stimulus to the kidney, in fact frequently occurs with a decreased stimulus, due to reflexly increased ventilation and a lowered $P_{\text{aCO}_2}$
- therefore, renal tubular cell pH is likely to be increased early in a metabolic acidosis
- in time the pH returns to normal, or actually decreases due to altered basolateral transport of $\text{H}^+$
- compensation is achieved as the mass of filtered bicarbonate is dramatically reduced and less $\text{H}^+$ ion secretion is required for $\text{HCO}_3^-$ reabsorption and the formation of titratable acid and ammonium, e.g.

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Acidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma $\text{HCO}_3^-$</td>
<td>24 mmol/l</td>
<td>12 mmol/l</td>
</tr>
<tr>
<td>Filtered $\text{HCO}_3^-$</td>
<td>4320 mmol/d</td>
<td>2160 mmol/d</td>
</tr>
<tr>
<td>Reabsorbed $\text{HCO}_3^-$</td>
<td>4315 mmol/d</td>
<td>2160 mmol/d</td>
</tr>
<tr>
<td>Total $\text{H}^+$ secreted</td>
<td>4375 mmol/d</td>
<td>2360 mmol/d</td>
</tr>
<tr>
<td>Titratable Acid &amp; $\text{NH}_4^+$</td>
<td>60 mmol/d</td>
<td><strong>200</strong> mmol/d</td>
</tr>
</tbody>
</table>

- thus, even in the presence of greatly reduced total acid secretion, the kidneys are able to compensate for metabolic acidosis
- the limiting factor for this compensation is the availability of buffer
- there is recent evidence that the rate of $\text{H}^+$ secretion in the collecting ducts may in fact be increased, despite the lowered $\text{CO}_2$, the mechanism is unknown but may involve aldosterone

**Metabolic Alkalosis**

- situation for alkalosis is exactly the opposite
- despite the reflexly elevated $P_{\text{aCO}_2}$ and increased $\text{H}^+$ secretion, the load of filtered $\text{HCO}_3^-$ becomes so great that much escapes reabsorption and little or no titratable acid or ammonium is formed
- there is some evidence that there may be active secretion of bicarbonate into the collecting ducts
- this description may not apply to chronic alkalosis
Other Factors Influencing Hydrogen Ion Secretion

- **Extracellular Volume Depletion**
  - presence of salt depletion and ECV contraction interferes with the ability of the kidney to compensate for a *metabolic alkalosis*, as may occur in high GIT obstruction
  - salt depletion not only stimulates Na⁺ reabsorption but also H⁺ secretion
  - this occurs mainly in the proximal segments, the mechanism is unclear but probably involves Na⁺/H⁺ counter-transport across the luminal membrane
  - therefore, all filtered HCO₃⁻ is reabsorbed and the metabolic alkalosis is uncompensated

  **NB:** salt depletion itself will *not* generate an alkalosis, merely impair the kidney's ability to compensate for such

  - the major reason for this is that salt depletion per se has little effect on the distal nephrons secretion of H⁺
  - isolated losses of Cl⁻, in addition to the above, maintain an alkalosis by stimulating hydrogen-ion secretion

- **Aldosterone Excess and Potassium Depletion**
  - aldosterone and other mineralocorticoids stimulate H⁺ secretion and ammonia production by a direct action on the DT and collecting ducts
  - this is distinct from their effects on Na⁺ & K⁺
  - this effect alone is relatively small but is physiologically significant as aldosterone,
    a. tonically facilitates H⁺ secretion (permissive effect)
    b. increases during metabolic acidosis and facilitates H⁺ secretion in the collecting ducts
    c. may contribute to the increased H⁺ secretion seen in salt depletion
      • although more proximal factors are more important

  - potassium depletion also stimulates H⁺ secretion and ammonia production, presumably by decreasing tubular cell pH
  - only when K⁺ depletion is extremely severe will *de novo* alter the renal acid-base balance
  - hypokalaemia decreases aldosterone secretion, tending to negate any increase in H⁺ secretion

  - the combination of hypokalaemia and hyperaldosteronism acts synergistically to markedly stimulate H⁺ secretion and thereby *generate* a metabolic alkalosis
  - this combination occurs in a number of clinical conditions,
    a. primary hyperaldosteronism       - may itself cause hypokalaemia
    b. extensive use of diuretics       - especially in CCF and cirrhosis

  - the later may be worsened by concurrent *salt depletion* stimulating the reabsorption of bicarbonate
  - the reverse can occur in patients unable to secrete aldosterone, ie. ensuing hyperkalaemia and modest metabolic acidosis
Cortisol and PTH

- when present in high concentration, cortisol will exert mineralocorticoid effects, ie.
  i. sodium retention
  ii. potassium depletion
  iii. metabolic alkalosis

- PTH exerts a direct effect on the PT inhibiting H⁺ ion secretion with ensuing loss of bicarbonate and metabolic acidosis

Influence of H⁺ Secretion on NaCl Reabsorption

- H⁺ ion secretion in the PT is directly coupled to countertransport of Na⁺
- ergo, were H⁺ ion secretion inhibited, Na⁺ reabsorption would decrease
- moreover, even in the distal segments, Na⁺ reabsorption is indirectly coupled to H⁺ ion secretion by the δ[EC]
- this stems from the fact that bicarbonate ions are ~ 25% of the anions in glomerular filtrate, unless reabsorbed at the same rate as Na⁺ a large charge separation occurs
- since bicarbonate is reabsorbed as a result of H⁺ ion secretion, there is, effectively an "exchange" of Na⁺ for H⁺ even in the absence of direct coupling
- this also occurs with the formation of titratable acid and ammonium, both of which increase the (+)'ve charge of the lumen and facilitate the reabsorption of Na⁺
- in effect, Na⁺ is either reabsorbed with Cl⁻ or in exchange for H⁺, thus,
  a. there is usually an inverse correlation between the excretion rates of bicarbonate and chloride
  b. whenever acid secretion is inadequate to effect bicarbonate reabsorption, there is usually an obligatory excretion of Na⁺

- increased renal excretion of Cl⁻ (a) is, therefore, one of the reasons plasma [Cl⁻] decreases during renal compensation for metabolic acidosis
- in (b), Na⁺ excretion is usually not as great as the losses of bicarbonate due to the increased K⁺ secretion induced by an alkalosis

- inhibition of carbonic anhydrase therefore reduces renal acid excretion, thereby causing an increased excretion of sodium, bicarbonate and water
- further, this alkalinizes the tubular cells, increasing K⁺ secretion so a large fraction of the excreted bicarbonate is accompanied by K⁺
ACID-BASE BALANCE

- the major problem in clinical assessment stems from **compensatory processes**
- multiple experimental observations of all primary acid-base disturbances is used to produce confidence bands (± 2SD) for assessment of blood gas measurements → **normogram**

**NB:** given $P_{aCO2}$ is proportional to the **product** of $[HCO_3^-]$.[$H^+$], as $P_{aCO2}$ increases or decreases, so the $[HCO_3^-]$ increases or decreases by dissociation, however, **not** to the same degree as it is the product $[HCO_3^-]$.[$H^+$] which is proportional, therefore, the ratio $[HCO_3^-]/P_{aCO2}$ alters with a resultant change in the pH

**Correction Factors**

- **metabolic acidosis**
  - i. $P_{aCO2}$ ~ last two digits of pH ≥ 7.10
  - ii. $\downarrow HCO_3^- ~ 10$ mmol/l → $\downarrow P_{aCO2} ~ 12$ mmHg

- **metabolic alkalosis**
  - i. $P_{aCO2}$ ~ last two digits of pH ≤ 7.60
  - ii. $\uparrow HCO_3^- ~ 10$ mmol/l → $\uparrow P_{aCO2} ~ 7$ mmHg
  - iii. less well compensated due to hypoxia 2° to hypoventilation

- **acute respiratory acidosis**
  $$\uparrow P_{aCO2} ~ 10$$ mmHg → $\uparrow HCO_3^- ~ 1-2$ mmol/l

- **chronic respiratory acidosis**
  $$\uparrow P_{aCO2} ~ 10$$ mmHg → $\uparrow HCO_3^- ~ 4$ mmol/l

- **acute or chronic respiratory alkalosis**
  $$\downarrow P_{aCO2} ~ 10$$ mmHg → $\downarrow HCO_3^- ~ 2.5$ mmol/l

  **NB:** low $P_{aCO2}$ + normal $\delta P_{A-aO2}$ = central hyperventilation
  low $P_{aCO2}$ + high $\delta P_{A-aO2}$ = probable pulmonary disease
Respiratory Acidosis

- **Aetiology**
  
a. alveolar hypoventilation
  
i. decreased $V_M$  
  - CNS, spinal cord, motor neurones  
  - NMI, myopathies  
  - chest wall, pleural cavity, lung parenchyma, airways  
  - drugs, poisons
  
ii. increased $V_D$  
  - alveolar / anatomical  
  - equipment
  
b. increased FiCO$_2$  
  - low FGF  
  - exhausted soda lime  
  - unidirectional valve malfunction
  
c. increased CO$_2$ production  
  - fever  
  - thyrotoxicosis  
  - MH  
  - TPN

- **Blood Gasses**

\[ \uparrow P_{aCO_2} \rightarrow \uparrow [HCO_3^-] \text{ by dissociation, but} \]
\[ \text{ratio of } [HCO_3^-] / P_{aCO_2} \text{ falls} \rightarrow \downarrow \text{pH} \]

- increased $P_{aCO_2}$, and to a lesser extent increased $[H^+]$  
- thus, HCO$_3^-$ reabsorption is increased and more H$^+$ ion is excreted with phosphate and NH$_3$  
- Cl$^-$ is the anion which accompanies these and subsequent hypochloraemia may ensue

- the $\uparrow [HCO_3^-]$ compensates for the respiratory acidosis but is rarely complete  
- the extent of renal compensation is determined by the base excess

- as the bicarbonate system is "unavailable" to moderate changes in pH, most of the buffering is intracellular  
  $\rightarrow$ protein & phosphate

- in RBC’s the protons formed from the dissociation of carbonic acid are buffered by Hb and the HCO$_3^-$ formed diffuses into plasma

- Cl$^-$ enters the cells to maintain electroneutrality  
  $\rightarrow$ chloride shift  
  $\rightarrow$ $\uparrow$ RBC size & venous Hct. ~ 3%
Acute Chronic

<table>
<thead>
<tr>
<th></th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>decreased</td>
<td>≤ 7.4</td>
</tr>
<tr>
<td>(P_{aO2})</td>
<td>± low</td>
<td>± low</td>
</tr>
<tr>
<td>(P_{aCO2})</td>
<td>increased</td>
<td>increased</td>
</tr>
<tr>
<td>(HCO_3^-)</td>
<td>increased</td>
<td>increased</td>
</tr>
<tr>
<td>BE</td>
<td>increased</td>
<td>increased</td>
</tr>
</tbody>
</table>

1 mmol/10 mmHg \(P_{aCO2}\)
3-4 mmol/10 mmHg \(P_{aCO2}\)

Respiratory Alkalosis

Aetiology

- **normal \(\delta P_{A-aO2}\) gradient** = *non-pulmonary*
  - i. physiological
    - pregnancy
    - high altitude
  - ii. CNS disease
    - CVA, trauma
  - iii. drugs
    - salicylates
    - catecholamines
    - progesterone
    - analeptics
  - iv. thyrotoxicosis
  - v. endotoxaemia
  - vi. psychogenic hyperventilation
  - vii. severe anaemia
  - viii. IPPV

- **high \(\delta P_{A-aO2}\) gradient** = *pulmonary*
  - i. ARDS, septicaemia
  - ii. hepatic failure
  - iii. pulmonary emboli
  - iv. pulmonary oedema
  - v. lung disease + increased work of breathing
    - asthma, emphysema

NB: any given cause may have both pulmonary and non-pulmonary components, eg. pregnancy
**Blood Gases**

\[ \downarrow P_{aCO2} \rightarrow \downarrow [HCO_3^-] \] by dissociation, but

\begin{align*}
\text{ratio of } [HCO_3^-] / P_{aCO2} \text{ rises } & \rightarrow \uparrow pH \\
\end{align*}

<table>
<thead>
<tr>
<th></th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>increased</td>
<td>≥ 7.4</td>
</tr>
<tr>
<td>(P_{aO2})</td>
<td>normal</td>
<td>normal</td>
</tr>
<tr>
<td>(P_{aCO2})</td>
<td>decreased</td>
<td>decreased</td>
</tr>
<tr>
<td>[HCO_3^-]</td>
<td>decreased 2 mmol/10 mmHg (P_{aCO2})</td>
<td>decreased 5 mmol/10 mmHg (P_{aCO2})</td>
</tr>
<tr>
<td>BE.</td>
<td>normal</td>
<td>decreased</td>
</tr>
</tbody>
</table>

- decreased \(P_{aCO2}\) inhibits renal tubular H\(^+\) secretion
- thus some bicarbonate escapes reabsorption and less H\(^+\) is available for the formation of titratable acid and ammonium \(\rightarrow\) the urine becomes alkaline
- decreased plasma [HCO_3\(^-\)] compensates for respiratory alkalosis and may be nearly complete
- extent of renal compensation determined by base deficit, or negative base excess
Metabolic Acidosis - Aetiology

**Increased Non-Respiratory Acids**

1. **increased intake**
   
i. anion gap > 18

<table>
<thead>
<tr>
<th>Acid</th>
<th>Anions¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salicylates</td>
<td>• salicylate, lactate, ketoacids</td>
</tr>
<tr>
<td>Ethanol</td>
<td>• acetoacetate, lactate</td>
</tr>
<tr>
<td>Methanol</td>
<td>• formate², lactate</td>
</tr>
<tr>
<td>Paraldehyde</td>
<td>• formate, acetate, lactate, pyruvate</td>
</tr>
<tr>
<td>Xylitol, Fructose</td>
<td>• lactate</td>
</tr>
<tr>
<td>Sorbitol</td>
<td></td>
</tr>
<tr>
<td>Ethylene glycol</td>
<td>• oxalate</td>
</tr>
</tbody>
</table>

¹ these are usually associated with the production of acid at some stage
² rationale for administration of ethanol for methanol toxicity is competition for alcohol dehydrogenase & ↓ production of formate

ii. anion gap < 18

- always due to accumulation of HCl
- ie. Cl⁻ accumulates as HCO₃⁻ falls → **hyperchloraemic**
- usually **hyperkalaemic**
- cationic amino acids → Arginine & Lysine HCl
- ammonium chloride → urea & HCl in the liver
- in liver failure → hyperammonaemia
- IV HCl used to sterilise central lines
- mineralocorticoid deficiency
- "potassium sparing" diuretics
2. *increased production*  \(\rightarrow\) anion gap > 18

<table>
<thead>
<tr>
<th>Acidosis</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoacidosis</td>
<td>• diabetic ketoacidosis</td>
</tr>
<tr>
<td></td>
<td>• alcoholic ketoacidosis</td>
</tr>
<tr>
<td></td>
<td>• starvation</td>
</tr>
<tr>
<td>Lactic acidosis</td>
<td>• types A&amp;B ± normal anion gap</td>
</tr>
<tr>
<td></td>
<td>• cardiorespiratory failure</td>
</tr>
<tr>
<td></td>
<td>• sepsis, major trauma</td>
</tr>
<tr>
<td></td>
<td>• toxins, drugs - eg. phenformin</td>
</tr>
<tr>
<td></td>
<td>• enzyme defects</td>
</tr>
</tbody>
</table>

3. *decreased excretion*  \(\rightarrow\) anion gap > 18
• renal failure with retention of SO\(_4^–\)/HPO\(_4^–\) acids

### Decreased Bases

1. *increased renal losses*  *normal anion gap / ↑ Cl⁻*
   i. carbonic anhydrase inhibitors
   ii. renal tubular acidosis
      • proximal  \(\rightarrow\) equilibrium, *no* \(R_X\) with \(HCO_3^-\)
      • distal  \(\rightarrow\) requires \(R_X\) with \(HCO_3^-\)
   iii. early uraemia

2. *increased GIT losses*
   i. diarrhoea
   ii. SI fistulae
   iii. ureterosigmoidoscopy

### Dilutional Acidosis

- if large volumes of low \(HCO_3^-\) fluids are given a metabolic acidosis will appear
- this is due to the fact that \(CO_2\) readily diffuses into the solution which then attains a pH \(\sim\) 4.9
- it then takes the addition of \(~\) 24 mmol/l of \(HCO_3^-\) to raise the pH to 7.4
- Hartman's solution was designed with this in mind, containing 28 mmol/l of lactate, which is metabolised in the liver to \(HCO_3^-\)
- lactate is present as the *sodium salt* of the acid anion, therefore cannot generate an acidosis in its own right

*NB:* when hepatic blood flow is low and metabolism slow, the plasma lactate level may rise, however lactate itself is not toxic
Blood Gases

\[ [H^+] \text{ increases, or } [HCO_3^-] \text{ decreases } \rightarrow \text{ plasma } [HCO_3^-] \text{ decreases} \]

\textit{ratio} of \([HCO_3^-]/P_{aCO2}\) falls \rightarrow \text{ decreasing pH}

<table>
<thead>
<tr>
<th></th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>decreased</td>
<td>(\leq 7.4)</td>
</tr>
<tr>
<td>(P_{aO2})</td>
<td>normal</td>
<td>normal</td>
</tr>
<tr>
<td>(P_{aCO2})</td>
<td>normal</td>
<td>decreases*</td>
</tr>
<tr>
<td>(HCO_3^-)</td>
<td>decreased</td>
<td>± decreased</td>
</tr>
<tr>
<td>BE.</td>
<td>negative</td>
<td>negative</td>
</tr>
</tbody>
</table>

*12 mmHg/10 mmol \([HCO_3^-])_{pl}^\text{nl}*

\(NB:\) \(P_{aCO2} \approx \text{ last two digits of } \text{pH} \geq 7.10\)

\(\downarrow \text{HCO}_3^- \approx 10 \text{ mmol/l} \rightarrow \downarrow \text{P}_{aCO2} \approx 12 \text{ mmHg}\)

- decreased pH stimulates ventilation, predominantly via \textit{peripheral chemoreceptors}, decreasing \(P_{aCO2}\) and compensating the acidosis
- the kidney increases excretion of titratable acid \textit{despite} the decrease in \(P_{aCO2}\)
- this occurs as the filtered load of \(HCO_3^-\) decreases to a greater extent than the reduction in distal tubular \(H^+\) secretion

\(\rightarrow \) more \(H^+\) is available for titration against \(NH_3\) and \(HPO_4^{2-}\)

- the decreased plasma \([HCO_3^-]\) shows as a \textit{base deficit}

\(\textbf{Treatment}\)

a. ABC
b. treatment of the causative factor
c. \(NaCl 0.9\%\)
   - if the acidemia is not affecting cardiac function, giving \(NaCl\) will allow the kidney to excrete \(HCl\)
d. \(Na\)-Bicarbonate 8.4% - see below
e. dialysis
Bicarbonate Administration

NB: "unanimous feeling that the routine administration of bicarbonate was counterproductive" AHA (JAMA 1986)

- no studies demonstrate a benefit in outcome, most show deleterious effects
- 100 mmol of HCO$_3^-$ produces 2.24l of CO$_2$, therefore the P$_{aCO_2}$ will rise if ventilation is fixed
- is only the RX of choice where the origin of the acidaemia is loss of bicarbonate
- the dose of HCO$_3^-$ is usually calculated on the empirical assumption that the ion has a V$_D$ ~ 50% of body weight
- this takes into account diverse buffer reactions in both ECF & ICF
- initial correction should be aimed at ≤½ this amount as the initial action is in the ECF
- the AHA recommendations for administration include,

1. CPR > 10 minutes
2. only when an increase in V$_M$ is possible (ie. ventilated)
3. AGA's → pH < 7.0
4. RX ≤ 1 mmol/kg slowly IV
5. VF associated with,
   i. TCA overdosage
   ii. hyperkalaemia

- potential problems associated with administration include,

1. produces a paradoxical ICF acidosis
2. may produce an ECF alkalosis,
   i. shifts the HbO$_2$ curve to the left, decreasing O$_2$ availability at a cellular level
   ii. shifts K$^+$ into cells and may result in,
      • hypokalaemic cardiotoxicity in K$^+$-depleted patients
      • tetany in renal failure or Ca$^{2+}$ depletion
3. the solution is hyperosmolar, 1M → 50 ml = 50 mmol
   • the excessive Na$^+$ load may result in cardiovascular decompensation ± CCF
4. CSF equilibrates slowly with [HCO$_3^-$]$_{pl}$, therefore ventilation may be maintained despite the increase in [HCO$_3^-$]$_{pl}$, resulting in a respiratory alkalosis
5. where the acidaemia is due to organic acids, the subsequent metabolism of such acids and regeneration of HCO$_3^-$ will produce a metabolic alkalosis
**Bicarbonate - Clinical Uses**

1. treatment of *hyperkalaemia*  
   - $K^+ \geq 6.0 \text{ mmol/l}$  
   - respiratory insufficiency  
   - widened QRS / P wave loss

2. treatment of arrhythmias in *tricyclic overdose*

3. alkalinising the urine  
   i. drug overdose  
      - phenobarb, salicylates  
   ii. rhabdomyolysis

4. treatment of  
   i. acidosis  
      - $2^{\circ}$ HCO$_3^-$ loss  
         - type 1 RTA  
         - diarrhoeal or fistula losses from SI  
   ii. neonatal/paediatric cardiac arrest  
   iii. severe persistent acidosis  
      - $\text{pH} < 7.0^{\circ}$  
      - lactic acidosis  
      - prolonged severe ketoacidosis  
      - neonatal cardiorespiratory failure + severe acidosis  
      - **no proven benefit, probably harmful**

*NB:* non-CO$_2$ producing agents may be of benefit, eg. carbicarb, THAM, dichloroacetate  
→ however, studies show no significant benefit in outcome
Metabolic Alkalosis

- **Aetiology**

  - **NB:** commonly associated with *hypovolaemia* and/or *hypokalaemia*

  a. any *fluid loss* replaced with insufficient Na⁺ → H⁺ excretion
  b. *acid loss* is either renal or GIT
  c. common causes - diuretics
    - vomiting
    - following correction of hypercarbia
  d. *increased proton losses*
    i. renal - ↑ Na⁺ reabsorption (hypovolaemia, dehydration, etc.)
    - hyperaldosteronism
    - steroid / ACTH secreting tumours
    - Cushing's syndrome
    - Barter's syndrome (JGA hyperplasia)
    - hypercalcaemia / hypomagnesaemia → NDI
    - drugs: steroids
      - diuretics
      - carbenoxolone
    ii. GIT - N/G suctioning
      - protracted vomiting
      - occasionally diarrhoea
  e. *increased bases*
    i. administration of NaHCO₃
    ii. metabolic conversion of exogenous acid anions - citrate
      - lactate
      - acetate
    iii. milk/alkali syndrome
    iv. renal conservation of HCO₃⁻ - acidosis
      - hypercarbia
  f. factors tending to *maintain* an alkalosis
    i. hypovolaemia
    ii. hypochloraemia
    iii. hypokalaemia
    iv. hypomagnesaemia
    v. chronic hypercapnia
    vi. mild chronic renal failure
- **Chloride Responsiveness**
  1. chloride *responsive* alkalosis → ECF Na⁺ or Cl⁻ deficit
  2. chloride *resistant* alkalosis →
     i. ICF hypokalaemia and acidosis
     ii. ECF alkalosis with normo-volaemia & Cl⁻
     iii. renal failure

- **Blood Gasses**

  \[
  \downarrow [H^+] , \text{ or } \uparrow [HCO_3^-] \rightarrow \uparrow \text{[HCO}_3^-\text{]} \text{ plasma}
  \]

  ratio of \([HCO_3^-] / P_{aCO2}\) rises → \(\uparrow \text{pH}\)

<table>
<thead>
<tr>
<th></th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>increased</td>
<td>&gt; 7.4</td>
</tr>
<tr>
<td>(P_{aO2})</td>
<td>normal</td>
<td>normal ± low</td>
</tr>
<tr>
<td>(P_{aCO2})</td>
<td>normal</td>
<td>increases¹</td>
</tr>
<tr>
<td>(HCO_3^-)</td>
<td>increased</td>
<td>increased</td>
</tr>
<tr>
<td>BE.</td>
<td>positive</td>
<td>positive</td>
</tr>
</tbody>
</table>

¹ minimally due hypoxic drive

**NB:** \(P_{aCO2} \sim \) last two digits of \(\text{pH} \leq 7.60\)

\(\uparrow HCO_3^- \sim 10\text{ mmol/l} \rightarrow \uparrow P_{aCO2} \sim 7\text{ mmHg}\)

**this is the least well compensated form of acid-base disturbance**
**Treatment**

a. treat the causative factor

b. prevent tubular (PT) loss of H⁺ → increase *functional ECF*
   i. NaCl 0.9% ± KCl
   ii. NSA-5%, albumin or blood transfusion
   iii. inotropic support of cardiac output and GFR
   iv. acetazolamide

c. prevent DCT loss of H⁺
   i. replace K⁺ and Cl⁻ deficits
   ii. suppress aldosterone with spironolactone
   iii. triamterene, amiloride

d. addition of HCl to ECF
   i. IV HCl infusion ~ 200 mmol/l D₃W
      ~ 10-15 mmol/hr *centrally*
   ii. NH₄Cl - weak acid, pKₐ ~ 9.3
      - doesn't alter pH rapidly or require CVC line
      - NH₄⁺ dissociates and is metabolised to *urea*
      - H⁺ thus formed correcting the alkalosis
   iii. arginine-HCl, lysine-HCl - also metabolised to urea and HCl by liver

**Other Alkaloses**

1. *diuretic* induced alkalosis
   - is the result of *chloride deficiency* and is corrected by replacement
   - the body defends ECF volume by Na⁺ retention but if Cl⁻ is deficient then only HCO₃⁻ is available to maintain electroneutrality

2. *steroid* induced alkalosis
   - is the result of increased DT exchange of Na⁺ for K⁺ & H⁺
   - this leads to ECFV overload, hypokalaemia and alkalosis
   - chloride replacement does *not* correct this condition as the normal mechanisms for the excretion of HCO₃⁻ are interfered with

3. *hypokalaemia* and alkalosis
   - the evidence relating these is weak
   - mostly the two are associated rather than cause/effect, eg. thiazides
   - severe hypokalaemia may result in a form of nephrogenic DI which may lead to hypovolaemia, with subsequent increased aldosterone secretion

4. *hypercalcaemia* probably acts via the same mechanism

5. *hypomagnesaemia* may only be associated, eg. thiazides
CALCIUM

i. elemental alkaline earth metal
ii. atomic number = 20
iii. molecular weight ~ 40
iv. divalent cation - fifth most plentiful cation in the body

- total body content ~ **380 mmol/kg**, distributed as follows,
  a. ICF ~ 0.004%
  b. ECF ~ 0.01%
  c. bone ~ 99%
  d. exchangeable ~ 1%

- this equates to ~ 1100 g/average adult, ~ 27.5 mol of Ca^{++}
- the daily requirement in the adult ~ 0.11 mmol/kg
- concentration ranges vary between tissues,
  a. ECF ~ **2.2-2.8 mmol/l**
     i. 45% - ionised Ca^{++}
     ii. 15% - complexed to low MW anions (citrate, HPO_{4}^{2-})
     iii. 40% - reversibly bound to plasma proteins (alb, glob.)
        - non-filterable fraction
  b. ICF ~ 1 mmol/l total
     ~ 10^{-4} mmol/l as free ionised Ca^{++}
     ~ 99% bound to enzymes in SR, cisternae, & tubules

- only plasma ionised Ca^{++} is biologically active
- the most important influence on protein binding is **plasma pH**
- an increase of pH increasing the binding of Ca^{++} due to the exposure of more anionic sites
  \[\rightarrow\] decreased ionised Ca^{++}
Important Functions of Calcium

a. cytoplasm
   i. excitation contraction coupling in all muscle
   ii. enzyme cofactor
   iii. regulation of mitotic activity

b. cell membrane
   i. excitability of nerve / muscle membrane
      • setting the threshold $V_m$ for excitation
   ii. automaticity
      - smooth muscle
      - SA & AV nodes
   iii. neurotransmitter release at nerve terminals (NMJ)
   iv. neuro-hormonal release & activity
      • 1. $\alpha$-adrenergic
         - smooth muscle
         - hepatic glycogenolysis
         - salivary secretion
      • 2. ACh
         - smooth muscle
         - GIT, GB, bladder contraction
      • 3. ADH
         - smooth muscle ($V_i$)
      • 4. oxytocin
         - uterine & myoepithelial
      • 5. angiotensin II
         - aldosterone secretion from Z.G.
      • 6. CCK
         - pancreatic secretion
         - GB contraction
      • 7. histamine ($H_1$)
         - bronchial contraction
         - GIT smooth muscle contraction

c. extracellular
   i. coagulation cascade
      - I, II, VII, IX, X
   ii. complement cascade
   iii. bone & teeth formation
      - Ca$^{++}$ hydroxyapatite
**Effector Sites for Calcium Homeostasis**

a. **GIT**
   - *absorption* major variable under control
     ~ 1000 mg typical daily intake
     ~ 10% absorption
   - GIT secretes up to 600 mg/d
   - this is reabsorbed along with the above 10%

b. **kidney**
   - ~ 60% of plasma Ca\(^{++}\) is ultrafilterable
   - reabsorption throughout the nephron, except in the **DLH**, similar to Na\(^+\)
   - ~ 60% in the PT, remainder in the ALH and DT
   - ~ 98-99% of filtered mass is reabsorbed
   - ~ 5% of an increment in dietary Ca\(^{++}\) appears in the urine
   - reabsorption is under control of **PTH**
   - affected by large number of other inputs, especially Na\(^+\) and acid-base changes
   - there is some coupling of Na\(^+\)/Ca\(^{++}\) in the PT and ALH
   - this coupling is lost in more distal segments,
     i. **aldosterone** & **PTH** do not affect distal handling of both ions
     ii. **thiazides** inhibit distal Na\(^+\) reabsorption, however enhance Ca\(^{++}\) reabsorption
     iii. proximal or loop diuretics increase excretion of both ions
   - chronic **metabolic acidosis** markedly *increases* Ca\(^{++}\) excretion with subsequent loss from bone
   - alkalosis produces the opposite

c. **bone**
   - ~ 99% of total body Ca\(^{++}\) held as **hydroxyapatite**
   - interchanges of Ca\(^{++}\) between ECF and bone affect the internal distribution not body mass of Ca\(^{++}\)
   - acts as an enormous sink for exchange with the ECF

**Control Mechanisms**

a. \([\text{Ca}^{++}]\cdot[\text{HPO}_4^{--}]\) solubility product
   - product > 6 increases the likelihood of ectopic calcification
b. parathyroid hormone
c. vitamin D - 1,25 dihydroxycholecalciferol
d. calcitonin
Secondary Influences

a. steroids - decrease Ca$$^{++}$$
b. growth hormone - increase Ca$$^{++}$$
c. albumin levels - $$\sim 0.02 \text{ mmol Ca}^{++} / \text{gram albumin}$$ (0.2 mmol/10g)
d. acid-base status
i. acidosis - increases Ca$$^{++}$$
ii. alkalosis - decreases Ca$$^{++}$$
e. renal function - GFR
- tubular excretion
- 1-hydroxylation of 25-(OH)-D$_3$
f. thyroid hormones - increase Ca$$^{++}$$
g. glucagon - decrease Ca$$^{++}$$

Hormonal Control of Effector Sites

a. parathyroid hormone
i. increases movement of Ca$$^{++}$$ and HPO$_4^{-}$ out of bone
ii. increases renal tubular reabsorption of Ca$$^{++}$$
iii. reduces renal tubular reabsorption of HPO$_4^{-}$
iv. stimulates production of Vit. D → indirect effects

- inhibits proximal tubular H$^+$ secretion & HCO$_3^-$ reabsorption
  → ↓ plasma pH → displaces Ca$$^{++}$$ from plasma protein
  increases bone reabsorption

- increased HPO$_4^{-}$ excretion aids further reabsorption from bone due effect on
  [HPO$_4^{-}$][Ca$$^{++}$$] solubility product

- NB: hyperparathyroidism causes,
i. an elevated plasma calcium with a low to normal phosphate
ii. enhanced bone reabsorption with cysts
iii. ectopic calcification
iv. renal stones
  • renal Ca$$^{++}$$ excretion increases, despite the elevated PTH,
    as the filtered mass increases >> the reabsorptive increase
b. **vitamin D**
   - actually a group of closely related *sterols*,
     
     $\begin{align*}
     7\text{-dehydrocholesterol} & \quad + \quad \text{UV light} \quad \rightarrow \quad D_3 \\
     D_3 & \quad + \quad \text{liver} \quad 25\text{-hydroxylation} \quad \rightarrow \quad 25\text{-(OH)}\text{-D}_3 \\
     25\text{-(OH)}\text{-D}_3 & \quad + \quad \text{kidney} \quad 1\text{-hydroxylation} \quad \rightarrow \quad 1,25\text{-(OH)}_2\text{D}_3
     \end{align*}$
   - by definition this is a *hormone* not a vitamin
   - also absorbed from the GIT, the plant form differing only slightly
   - *1-hydroxylation* is increased by PTH and a low plasma HPO$_4^-$
   - also increased by oestrogen and prolactin (pregnancy)
   - the major actions of vitamin D are,
     i. enhance GIT absorption of Ca$^{++}$ and HPO$_4^-$
     ii. enhance the reabsorption of Ca$^{++}$ and HPO$_4^-$ from bone
     iii. stimulates the renal tubular reabsorption of Ca$^{++}$
        (the significance of this is unsettled)
   - **NB:** *hypervitaminosis D*, results in an elevated Ca$^{++}$ and HPO$_4^-$

c. **calcitonin**
   - secreted by the *parafollicular cells* of the thyroid gland in response to a raised plasma Ca$^{++}$
   - lowers the plasma calcium principally by inhibiting bone reabsorption
   - overall contribution to homeostasis is *minor*
Hypocalcaemia

**Def'n:** total corrected Ca\(^{++}\) ≤ 2.1 mmol/l (R: 2.10-2.55 mmol/l)

**corrected calcium** ~ total \([\text{Ca}^{++}] + 0.02[44 - \text{albumin} \text{ (g/l)}]\) mmol/l

**ionised calcium** ≤ 1.20-1.30 mmol/l

### Aetiology

- **factitious** - hypoalbuminaemia (N: 37-55 g/l)
  - \(\text{Ca}^{++} \sim 0.01-0.02 \text{ mmol} / \downarrow 1\text{g per litre}\)
  - K\(^+\)-EDTA tube sample

- **acute** - respiratory alkalosis
  - primary hypoparathyroidism (post-surgical)
  - hypomagnesaemia (\(\downarrow\) PTH release)
  - acute pancreatitis, rhabdomyolysis, tumour lysis, MH
  - citrate toxicity

- **chronic** - renal failure
  - vit. D deficiency - reduced intake
  - liver / renal disease
  - vit. D resistance - renal disease
  - familial
  - high dietary HPO\(_4\)\(^{-}\) intake

### Aetiology **HPIM**

1. **PTH absent**
   - i. hereditary hypoparathyroidism
   - ii. acquired hypoparathyroidism
   - iii. hypomagnesaemia

2. **PTH ineffective**
   - i. chronic renal failure
   - ii. active vit.D lacking
     - \(\downarrow\) dietary intake or sunlight
     - defective metabolism - anticonvulsant therapy
     - vit.D-dependent rickets type I
   - iii. active vit.D ineffective
     - intestinal malabsorption
     - vit.D-dependent rickets type II - end-organ resistance
   - iv. pseudohypoparathyroidism

3. **PTH overwhelmed**
   - i. severe acute hyperphosphataemia - ARF, tumour lysis, rhabdomyolysis
   - ii. osteitis fibrosa following parathyroidectomy
### Clinical Features

- **CNS**
  - increased irritability, personality changes
  - oculogyric crises, extrapyramidal signs
  - tetany & **convulsions**

- **NMJ**
  - reduced threshold $V_m$
  - neuromuscular excitability
  - reduced ACh release NMJ
  - Chvostek’s sign, Trousseau’s sign
  - cramps ± tetany
  - stridor ± **laryngospasm**

- **CVS**
  - reduced SVR*
  - negative inotropy* → **hypotension**
  - negative chronotropy
  - prolonged $QT_c = QT / \sqrt{RR} < 0.45 \text{ s (female)}$
  - atrial & ventricular ectopics

- **other**
  - cataracts
  - rickets, osteomalacia
  - coagulopathy (very rare)

### Treatment

- **Ca Gluconate 10%**
  - $0.22 \text{ mmol/ml}$
  - ~ 2-4 mmol every 6-8 hrs
  - ~ $0.5 \text{ ml/kg to a maximum of 20 ml}$

- **CaCl$_2$ 10%**
  - $0.68 \text{ mmol/ml x 10 ml}$
  - the injection rate should be slow ≤ 1 ml/min
  - faster rates may → high concentration and cardiac arrest
  - this is an **acidifying salt**, therefore undesirable in the setting of renal insufficiency
  - the solution is very irritating and should never be injected into the tissues
  - injections are accompanied by peripheral vasodilation and vessel irritation

- **Vit. D**
  - calciferol ~ 1.25 mg twice weekly

- **R$_x$** of concomitant electrolyte abnormalities
  - hypomagnesaemia
  - hypokalaemia
Hypercalcaemia

**Def’n:** total corrected Ca\(^{++}\) > 2.6 mmol/l (R: 2.10-2.55 mmol/l)

**Corrected calcium** ~ total [Ca\(^{++}\)] + [0.02 x (44 - albumin (g/l))] mmol/l

**Ionised calcium** > 1.20-1.30 mmol/l

■ Aetiology

1. **factitious**
   - stasis
   - post-prandial
   - polycythaemia, dehydration, high plasma albumin

2. **common** ~ 90% of all cases
   i. hyperparathyroidism - 1\(^{°}\) & 3\(^{°}\)
   ii. neoplastic diseases
      - solid tumour with bony 2\(^{°}\)s - breast, prostate
      - ectopic parathormone - kidney, lung (~ 10-15%)
      - osteocyte activation factor - haematological malignancies
         - ?? PGE\(_2\), PTH-rP, OAF, IL-1, TNF, 1,25-(OH)\(_2\)-D\(_3\)

3. **parathyroid related**
   i. 1\(^{°}\) hyperparathyroidism - solitary adenomas
      - MEN I & II
   ii. lithium therapy ↑ parathyroid function (~ 10%)
   iii. familial hypocaliuric hypercalcaemia - auto.D, benign

4. **malignancy related**
   i. solid tumour with metastases
   ii. solid tumour with hormonally mediated hypercalcaemia
   iii. haematological malignancies - *m. myeloma*, leukaemia, lymphoma

5. **vitamin D related**
   i. vitamin D intoxication
   ii. ↑ 1,25-(OH)\(_2\)-D\(_3\) - sarcoid & other granulomatous diseases
      - TB, beryllosis
   iii. idiopathic hypercalcaemia of infancy

6. **increased bone turnover**
   - hyperthyroidism
   - *thiazide diuretics*
   - immobilisation
   - vitamin A intoxication

7. **associated with renal failure**
   - severe 2\(^{°}\) hyperparathyroidism
   - milk/alkali syndrome
   - aluminium intoxication

8. **other causes**
   - Addisonian crisis
   - phaeochromocytoma
   - excess IVT/TPN
**Clinical Features**

*NB:* initial polyuria, thirst, fatigue, nausea, vomiting & abdominal pain

a. CNS  
- mental disturbance  
- personality change  
- paraesthesia  
- headache, fever, increased thirst  

b. CVS  
- bradycardia  
- asystolic arrest  
- increased digoxin toxicity  
  
  ECG  
  - shortened QT_c  
  - bradyarrhythmias  
  - AV blockade  

c. NMJ  
- increased ACh release  
- increased excitation / contraction  
- increased threshold \( V_m \)  
  
  * but decreased sensitivity of motor EP  
  
  → weakness, fatigue, paralysis  

d. renal  
- polyuria  
- nephrogenic DI, 2° to impaired tubular reabsorption  
- nephrocalcinosis  

e. musculoskeletal  
- weakness, fatigue, paralysis  
- bone pain, arthralgia  

f. GIT  
- nausea, vomiting, abdominal pain  
- constipation, anorexia, weight loss  
- gastric hyperacidity, peptic ulcer  
- pancreatitis

**Treatment**

a. ABC  
- ventilatory/CVS support  

b. correct dehydration  
- replace deficit with normal saline  

c. initiate diuresis  
- N.Saline at 4-6 l/d  
- frusemide 20-40 mg IV q4-8h  
  
  * hypokalaemia, hypomagnesaemia  

d. corticosteroids  
- ↓ GIT absorption / increase excretion  
  
  - not effective in 1° hyperparathyroidism  

e. diphosphonate  
- etidronate  

f. correct ↓ \( \text{HPO}_4^2^- \)  
- ↑ GIT absorption  
- ↓ bone uptake & ↑ reabsorption  

g. decrease bone release  
- calcitonin  
- mithramycin
PHOSPHATE

- involved in most metabolic processes and is a major constituent of bone
- normal adult content ~ 1000 g, of which 85% is in bone
- present in plasma as inorganic phosphate ~ 0.9-1.5 mmol/l
- there is diurnal variation in the level, even during fasting
- ethanol can induce phosphate depletion despite adequate intake
- HPO$_4^{-}$ is well absorbed from the GIT
- urinary excretion is the major homeostatic regulator for total body phosphate balance
  • ~ 5-12% is protein bound, therefore ~ 90% is filterable at the glomerulus
  • ~ 75% is actively reabsorbed, mostly in the PT in co-transport with Na$^+$
- there is no conclusive evidence for tubular secretion of phosphate
- the reabsorptive $T_{max}$ for phosphate is very close to normal filtered load
- therefore even small increases in the plasma concentration result in relatively large increases in renal excretion
- there is increased loss with mechanisms which increase Na$^+$ loss and also with 1° hyperparathyroidism
- the reabsorptive rate and $T_{max}$ alter over time, in response to alterations in plasma phosphate levels, not as a result of PTH or Vit.D
- the mechanism for this change is still unclear

- factors affecting tubular reabsorption of phosphate are,
  a. PTH  ↓
  b. Glucagon  ↓
  c. Dietary Phosphate  ↓
  d. 1,25-(OH)$_2$D$_3$  ↑
  e. Insulin  ↑
Hyperphosphataemia

Def’n:  $\text{H}_2\text{PO}_4^- > 1.35 \text{ mmol/l}$

Aetiology

a. acute  = release from cells
   i.  metabolic acidosis
   ii.  diabetic ketoacidosis
   iii. rhabdomyolysis
   iv.  ischaemic gut
   v.  severe catabolic states
   vi.  tumour lysis syndrome

b. chronic
   i.  renal failure
   ii.  hypoparathyroidism / pseudohypoparathyroidism
   iii.  vitamin D toxicity
   iv.  excessive intake - TPN
        - diphosphonate therapy

occurs more commonly in infants, children and post-menopausal women
clinical effects include,

a. hypocalcaemia  - $[\text{Ca}^{++}][\text{HPO}_4^-] < 5$

b. ectopic calcification  - arteries, skin
   - kidneys, nephrocalcinosis

c. keratopathy

d. $2^\circ$ hyperparathyroidism - renal osteodystrophy

treatment depends upon renal function,

a. normal  - diuresis

b. renal failure  - oral Al(OH)$_3$ & dialysis
Hypophosphataemia

Def’n:  $\text{H}_2\text{PO}_4^- \leq 0.8 \text{ mmol/l}$

- **Aetiology**
  
a. **acute**  $\propto$ entry into cells
    i. respiratory alkalosis  - any cause
    ii. insulin  - post-prandial, R$_x$ of hyperkalaemia, DKA 
      - glucagon, adrenaline, androgens, cortisol, anovulatory hormones
    iii. R$_x$ of acidosis  - diabetic ketoacidosis
      - rhabdomyolysis
      - hypercapnia
    iv. nutritional  - TPN in malnourished or anorexic patient
      - glucose, fructose, lactate, AA’s, glycerol
  
b. **acute**  $\propto$ increased loss / utilisation
    i. phosphaturia from diuresis  - osmotic / diuretic
    ii. severe illness  - sepsis, hypercatabolic states
      - recovery from hypothermia
  
c. **chronic**
    i. decreased intake  - rickets, osteomalacia
      - prolonged TPN
      - alcoholics
      - anorexia
    ii. decreased absorption  - vitamin D deficiency
      - intestinal dysfunction
      - steatorrhoea/malabsorption
    iii. increased loss  - diuresis
      - 1$^\circ$ hyperparathyroidism
      - renal tubular acidosis
    iv. increased utilisation  - hypercatabolic states, multitrauma
      - cancer, lymphoma & leukaemia especially

- **Symptoms**
  
a. asymptomatic
  
b. anorexia, dizziness
  
c. weakness, paraesthesia, bone pain (osteomalacia)
  
d. dyspnoea  - respiratory muscle weakness
**Clinical Signs**

1. proximal myopathy
2. waddling gait
3. paraesthesia
4. anaemia
5. respiratory insufficiency, failure
6. cardiac failure

**"Clinical Syndromes" of Hypophosphataemia**

a. "GBS-like syndrome" - acute muscular weakness
   - respiratory insufficiency / failure to wean
   - nervous system dysfunction
b. haematological - low 2,3-DPG & intracellular ATP
   - haemolysis
   - left shift HbO₂ curve
   - WBC dysfunction
c. neurological - peripheral neuropathy
   - CNS dysfunction
   - paraesthesia, waddling gait
   - epilepsy
d. metabolic acidosis & osteomalacia
e. myocardial dysfunction & cardiac failure

**Treatment**

a. $\text{H}_2\text{PO}_4(\text{K}^+)$ ~ 50-100 mmol/day
b. $\text{H}_2\text{PO}_4(\text{K}^+)$ ~ 30 mmol/2-3 hrs in DKA
c. also available is NaH₂PO₄
MAGNESIUM

i. elemental alkaline earth metal
ii. atomic number = 12
iii. molecular weight ~ 24.3
iv. divalent cation - second most plentiful intracellular cation

• total body content ~ 15 mmol/kg, (~ 1000 mmol/70 kg) distributed as follows,
  i. ICF ~ 45%
     ~ 2.5-15 mmol/l - highly variable
  ii. ECF ~ 5%
      • plasma ~ 0.75-1.1 mmol/l ~ 35% protein bound
  iii. bone ~ 50%
  iv. exchangeable ~ 65-70%

  NB: ICF and ECF concentrations may vary independently of each other,
  ∴ a significant deficit in one may be accompanied by minimal change in the other

• about 1/3 of the bone pool is exchangeable, far more readily in children than adults

■ Absorption & Excretion
  • average daily requirement ~ 0.04 mmol/day
  • the average adult ingests ~ 10-20 mmol Mg"/d
    ~ 3-6 mmol/d of this is absorbed across the GIT
  • this occurs predominantly in the upper SI via an active process, possibly linked to Ca"
  • Mg" is excreted principally by the kidney → freely filtered
  • the majority is reabsorbed in the PT → ~ 3-5% appears in the final urine
  • control mechanisms for homeostasis are poorly understood,
    a. PTH & vit.D increase GIT absorption
    b. follows Ca" flux in bone
    c. follows K+ flux across cells
    d. excreted by GFR, ∴ increased by diuretics
    e. lost in diarrhoea, intestinal fistulae

■ Important Functions of Magnesium
  a. neuromuscular function and excitability
  b. Na+/K+ -ATPase pump cofactor
  c. enzyme cofactor - anabolic functions in brain & liver
  d. involved in all phosphate transfer reactions
  e. release of hormones - PTH
Hypomagnesaemia

**Def'n:** plasma Mg$$^{++}$$ < 0.7 mmol/l

- **Aetiology**
  a. factitious - haemodilution
     - severe hypoalbuminaemia
  b. common - GIT losses
     - diuretics, renal failure
  c. acute
     i. β-adrenergic agonists - catecholamines
     ii. diarrhoea, vomiting, SI fistulae
     iii. acute pancreatitis
  d. chronic
     i. nutritional - NBM
     - prolonged Mg$$^{++}$$ deficient TPN
     - protein/calorie malnutrition
     - infants given cows milk (HPO$_4^{-}$:Mg$$^{++}$$)
       - enteral treatment of hypocalcaemia, with concomitant Mg$$^{++}$$ deficiency and reduced absorption of the later
     ii. cirrhosis & chronic alcoholism
     iii. GIT - diarrhoea, malabsorption
     - SI fistulae
     - NG aspiration
     iv. drugs - diuretics
     - gentamicin, other aminoglycosides
     - cis-platinum
     v. endocrine - hyperthyroidism
     - hyperaldosteronism
     - hyperparathyroidism + osteitis fibrosa cystica
     - diabetes mellitus
     vi. renal - chronic diseases
     - haemodialysis / haemoperfusion
     vii. SIADH
     viii. familial hypomagnesaemia

- Mg$$^{++}$$ deficiency is therefore frequently accompanied by hypokalaemia and hypocalcaemia
- Mg$$^{++}$$ frequently follows K$$^+$$ in the ICF environment
- when deficits of Mg$$^{++}$$ and K$$^+$$ coexist, Mg$$^{++}$$ repletion is often required to correct the later

**NB:** the interaction of the two ions is thought to be mediated by the effects of adrenal steroids on renal excretion
Clinical Manifestations

a. enzyme systems - Mg\(^{++}\) is a vital cofactor for,
   i. all nucleotide-PO\(_4\)\(^{--}\) transfer reactions
   ii. reversible association of intracellular particles
   iii. association macromolecules with subcellular organelles
      eg., mRNA to ribosomes
      → there is a decrease in energy substrate utilisation

b. CNS
   i. increased irritability
   ii. disorientation, psychotic behaviour
   iii. athetosis, nystagmus, tremor
   iv. twitching, tetany ± convulsions

c. renal
   i. microlith formation in the thick ALH
   ii. damage to tubular cells
   iii. ± hypokalaemia / hypocalcaemia

d. neuromuscular function
   i. increased release of ACh from motor neurones
   ii. increased sensitivity of the motor EP to applied ACh
   iii. neuromuscular excitability ± tetany

e. CVS
   i. ± decreased levels of K\(^{+}\) in cardiac cells
   ii. ± susceptibility to toxicity with cardiac glycosides
   iii. changes to cardiac muscle → decreased contractility
   iv. tachyarrhythmias → AF, SVT, torsade de pointes

f. hypocalcaemia 2° to decreased PTH release

Treatment

a. remove causative factor

b. enteral supplementation - Mg\(^{++}\) citrate, sulphate & hydroxide

c. parenteral supplementation → MgSO\(_4\)
   • the dose is expressed in terms of the hydrated salt,
     \[ 1.0g \ MgSO_4 \cdot (H_2O)_7 \rightarrow 4.06 \text{ mmol Mg}^{++} \]
   • * acute administration ~ 0.5-1.0 mmol/kg over 4 hrs
     ≤ 0.5 mmol/min
     ≤ 15-20 mmol/d, in two divided doses
   • available as ampoules 10 mmol/5 ml ~ 2.5g
Hypermagnesaemia

- **Causes**
  
a. increased intake - most common causes
   
i. Mg$^{++}$ containing cathartics & antacids
      
      • especially seen with renal impairment
      
      • these undergo rapid absorption in patients with large gastro-jejunal stomas
   
   ii. MgSO$_4$ administration for pre-eclampsia/eclampsia
   
   iii. inappropriate IVT / TPN replacement
  
b. decreased excretion
   
i. renal impairment - any cause
   
   ii. hypoadrenalism
  
c. compartmental shifts - rarely a cause
   
i. metabolic acidosis & diabetic ketoacidosis
   
   ii. hypothermia

- **Clinical Manifestations**
  
a. CNS
   
   • a number of effects are ≡ to those of Ca$^{++}$ → sedation & confusion
   
   • the flaccid, anaesthesia-like state following large doses is probably due to peripheral NMJ blockade
  
b. NMJ
   
   • direct depressant effect on skeletal muscle
   
   • decreased release of ACh from motor neurones
   
   • reduces the sensitivity of the motor EP → muscular weakness
   
   • depressed deep tendon reflexes ± respiratory paralysis (> 7 mmol/l)
      
      • of these the second is the most important
      
      • these effects are antagonised by Ca$^{++}$
  
c. CVS
   
   • increased conduction time → PR, QRS and QT prolongation (> 5 mmol/l)
   
   • decreased discharge rate of SA node
   
   • may abolish digitalis induced VPC’s
   
   • peripheral vasodilatation ~ direct vascular effect & ganglionic blockade
      
      → hypotension, conduction disturbances ± complete heart block
d. neonate - depressed conscious state
- hypotonia
- respiratory difficulties
→ low Apgar scores

NB: in infants experiencing hypoxia during delivery the unionised fraction increases and toxicity is enhanced

<table>
<thead>
<tr>
<th>Clinical Manifestations of Hypermagnesaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma Level</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>2.0-4.0 mmol/l</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>~ 5.0 mmol/l</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>~ 6.0 mmol/l</td>
</tr>
<tr>
<td>6.0-8.0 mmol/l</td>
</tr>
<tr>
<td>8.0-12.0 mmol/l</td>
</tr>
</tbody>
</table>

- **Treatment**

  a. ABC
  
  b. remove causative factor
  
  c. IV NaCl 0.9% - providing renal function is normal
     ~ 4-6 l/d
     ± add Ca++ 2.5-4.5 mmol/l
  
  d. CaCl₂ / Ca Gluconate ~ 2.5-5 mmol IV
     *cases of severe CVS, CNS or respiratory compromise
  
  e. frusemide ~ 20-40 mg IV
  
  f. haemodialysis
**Therapeutic Uses Of Magnesium**

a. hypomagnesaemia
   i. weakness & CNS signs
   ii. cardiac disturbance - torsade de pointes
       - digitalis induced VT
       - uncontrolled SVT
   iii. suspected severe depletion - alcoholics, malnourished
   iv. routine in TPN replacement

b. seizure states - pre-eclampsia/eclampsia
   - acute nephritis

c. uncontrolled hypertension

d. severe acute asthma

e. enteral preparations - cathartics
   - antacids